Diagnostic Challenges in Patients with Inborn Errors of Immunity with Different Manifestations of Immune Dysregulation

Karolina Pieniawska-Śmiech 1,2,*, Gerard Pasternak 2,3, Aleksandra Lewandowicz-Uszyńska 2,3 and Marek Jutel 1,4,*

1 Department of Clinical Immunology, Wroclaw Medical University, 50-368 Wroclaw, Poland
2 Department of Clinical Immunology and Paediatrics, Provincial Hospital J. Gromkowski, 51-149 Wroclaw, Poland; gerard.pasternak@umw.edu.pl (G.P.); aleksandra.lewandowicz-uszynska@umw.edu.pl (A.L.-U.)
3 3rd Department and Clinic of Paediatrics, Immunology and Rheumatology of Developmental Age, Wroclaw Medical University, 50-367 Wroclaw, Poland
4 ALL-MED Medical Research Institute, 53-201 Wroclaw, Poland
* Correspondence: karolina.pieniawska-smiech@student.umw.edu.pl (K.P.-Š.); marek.jutel@umw.edu.pl (M.J.)

Abstract: Inborn errors of immunity (IEI), formerly known as primary immunodeficiency disorders (PIDs), are inherited disorders caused by damaging germline variants in single genes, which result in increased susceptibility to infections and in allergic, autoimmune, autoinflammatory, nonmalignant lymphoproliferative, and neoplastic conditions. Along with well-known warning signs of PID, attention should be paid to signs of immune dysregulation, which seem to be equally important to susceptibility to infection in defining IEI. The modern diagnostics of IEI offer a variety of approaches but with some problems. The aim of this review is to discuss the diagnostic challenges in IEI patients in the context of an immune dysregulation background.

Keywords: allergy; autoimmunity; autoimmune lymphoproliferative syndrome; inborn errors of immunity; lymphoproliferation; malignancy; primary immunodeficiency

1. Introduction

Inborn errors of immunity (IEI), formerly known as primary immunodeficiency disorders (PIDs), are inherited disorders caused by damaging germline variants in single genes, resulting not only in increased susceptibility to infections but also in allergic, autoimmune, autoinflammatory, nonmalignant lymphoproliferative, and malignant manifestations. According to the most recent report by the International Union of Immunological Societies (IUIS), the identified IEI were classified in 10 tables with subtables segregating groups of disorders into overlapping phenotypes: (1) immunodeficiencies affecting cellular and humoral immunity (combined immunodeficiencies); (2) combined immunodeficiencies with associated or syndromic features; (3) predominantly antibody deficiencies; (4) diseases of immune dysregulation; (5) congenital defects of phagocyte number or function; (6) defects in intrinsic and innate immunity; (7) autoinflammatory diseases; (8) complement deficiencies; (9) bone marrow failure disorders; and (10) phenocopies of IEI. The 55 novel monogenic gene defects positioned in the last IEI update enhanced the total number of IEI to 485 [1,2].

The COVID-19 pandemic had an impact on various fields of medicine. In the context of clinical immunology and IEI, it has uncovered several new IEI [1]. Each time, the appearance of new pathogens is a potential challenge for the general population and also healthcare systems because of the lack of significant pre-existing immune memory. Similarly, in the case of pathogens learned about so far, patients with specific germline genetic variants (causing known and unknown IEI) may be more exposed to severe disease than the general population. Research on the COVID-19 pandemic course led to the detection of genes and mechanisms necessary for anti-SARS-CoV-2 immunity. About 2–3% of cases of severe SARS-CoV2 infection resulted from germline LOF/LOE variants in the
type 1 IFN signaling pathway: TLR3, UNC93B1, TICAM1, TBK1, IRF3, IRF7, IFNAR1, and IFNAR2 [1]. According to Asano et al., X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of severe COVID-19 among 1.8% of males below the age of 60 years [3].

The defects of the number or the function of immune system elements determine the clinical presentation of an IEI. Family history, as well as personal and clinical data, are considered a core element of patient initial management. Extensive anamnesis and clinical evaluation are the main tools for a suspected diagnosis of IEI [4]. The early diagnosis of IEI can be life-saving but remains challenging due to the low prevalence of these pathologies. This can result in the delay of diagnosis and consequently in a worse prognosis [5].

Disease manifestation appearance (i.e., Nijmegen breakage syndrome (NBS), Shwachman-Diamond syndrome, and DiGeorge syndrome), as well as subject growth during both in utero life and later, may suggest the diagnosis of IEI and provide an important diagnostic clue [6]. Severe and/or recurrent infections, consanguinity, or an unexplained death in one’s family are well-known signs of IEI; however, more attention should be paid to signs of immune dysregulation. Immune dysregulation is defined as a breakdown or malfunction of molecular control of immune system processes, and it is used to characterize an array of autoimmune and inflammatory conditions [7]. According to IUIS classification, there are 10 IEI categories based on their underlying molecular defect. One of them is called ‘diseases of immune dysregulation’. Moreover, it has been established that other patients with humoral, cellular, or innate immune system deficiencies are also at risk of autoimmune or inflammatory conditions [8]. Currently, signs of immune dysregulation are of great importance in defining IEI, as well as an increased tendency to infection.

The modern diagnostics of IEI include various diagnostic measures, such as a simple blood count with particular attention paid to the total absolute lymphocyte count, the serum immunoglobulin levels, and the complete sequencing of the exome or genome [9]. However, during the clinical evaluation of a patient with suspected or confirmed IEI, we should be aware of the possible problems and finer points that may restrict diagnosis in patients with IEI. The aim of this review is to summarize these diagnostic challenges, in particular, in the context of immune dysregulation in IEI patients.

2. Allergic Disease

Allergy develops on account of disturbed function of the immune system. The immune system depends on a complex balance of activation, to defend against invasive, foreign pathogens, and control, to differentiate between self and foreign matter. Allergic reactions are exaggerated immune responses against specific allergens [10,11]. The comorbidity of IEI and allergy appears because of the impairment of the immune system, leading to infectious susceptibility; however, it is still able to trigger an allergic response [8]. The mechanisms underlying the relationship between atopy and immunodeficiency are better recognized, thanks to the discovery and characterization of genetic variants, often showing “a new face of old disorders” [8]. Several studies indicated the potential mechanisms leading to such dysregulation, which include the failure of central thymic tolerance, an imbalance between the effector and regulatory T-cell function, a failure in the production of counter regulating interferon-gamma (IFN-γ), disturbed cytokine production, and possible differences in microbial colonization and infection patterns [8,12,13].

Thanks to growing interest in the coexistence of allergy and IEI, the topic has been investigated in a number of studies. However, the results are still inconsistent. For example, in one Iranian study atopic dermatitis (AD) was present in 52% of patients with selective IgA deficiency (sIgAD) [14], while among Brazilian patients with sIgAD, AD was found in 2.3% [8,15]. In the USIDENT study, AD was most commonly reported in patients with a deficiency of the nuclear factor κB (NFκB) essential modulator (62.5%), the Wiskott–Aldrich syndrome (WAS: 41.5%), combined immunodeficiency (CID: 33.3%), selective IgM deficiency (33.3%), and autosomal-dominant hyper-IgE syndrome (AD-HIES; 25%) [8,16]. A cohort study of patients with early onset severe combined immunodefi-
iciency due to adenosine deaminase deficiency (ADA-SCID) demonstrated that atopy was present in 56% of the patients, including mild AD in 11.1%. Severe AD was not a common feature [17]. A possible explanation of the diverse results are ethnic and geographical diversity and differences in methodological approaches.

Potential diagnostic difficulties may start even at the beginning in diagnosing IEI. An underlying, sometimes severe immune deficiency can manifest as common allergic symptoms, and IEI may masquerade allergic atopic patients [10]. In clinical practice, there are few warning signs of an underlying IEI among atopic phenotypes, and these include severe atopic disease, usually with a poor response to standard therapies, early-onset of the disease, a positive family history for IEI and/or severe familial atopy, and immunological abnormalities [11].

The standard screening tests for antibody deficiency include the measurement of immunoglobulin, IgG, IgA, and IgM levels in serum and the interpretation according to age-related reference values [18]. The routine measurement of serum IgE is not obligatory in the management of patients with suspected antibody deficiency and a history of recurrent infections. Previously, the level of total IgE was considered as a marker to catch allergic patients, but because it is nonspecific, it cannot confirm the allergy status of a patient [19,20]. Non-immunodeficient patients have variable IgE concentrations associated with atopic disease such as allergic rhinitis (AR), asthma, food allergy (FA), and AD, as well as other conditions, including parasitic disease [21]. However, in the context of PID, IgE measurement plays a role, especially in patients with concomitant eczema. Elevated IgE is common in a number of IEI, such as HIES, WAS, Netherton syndrome, immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, and Omenn syndrome [22]. One phenotype of complete DiGeorge syndrome, which is known as atypical complete DiGeorge syndrome, has oligoclonal T cell expansion with elevated IgE levels with concomitant generalized rash and lymphadenopathy [23]. The pathophysiological role of increased IgE in these disorders was not clearly characterized; however, there are few hypotheses [13]. Increased IgE production is associated not only with well-defined genetic syndromes but also with humoral, cellular, innate, and combined immunodeficiency disorders [5]. However, a high IgE (>180 IU/mL) is very rare in common variable immunodeficiency (CVID) (0.3% of patients) [21].

There are particular PIDs associated with atopy, especially eczema and elevated serum IgE, which can be confirmed by genetic tests and the identification of specific mutations. Mutations in the WAS gene on the X chromosome, which encodes the WAS protein (WASP), are a cause of Wiskott–Aldrich syndrome, characterized by recurrent infections, thrombocytopenia with small platelets, and eczema [8]. The mechanism for atopy in WAS is not fully described; however, impairment of regulatory T-cell (Treg) function is a possible contributor [8,24–26]. In total, 33% of patients with WAS and 20% of patients with X-linked thrombocytopenia (XLT) had positive food allergen-specific IgE (sIgE), in a study conducted by Lexmond et al. [8,27]. Food sensitization was generally detected with greater sensitivity using sIgE testing than by skin prick testing (SPT).

A dominant-negative heterozygous mutation in signal transduction and the activator of transcription 3 (STAT3) leads to autosomal-dominant hyper-IgE syndrome (AD-HIES), previously known as Job syndrome, with characteristic features such as chronic eczema, recurrent staphylococcal skin infections, pneumonia, increased serum IgE, and eosinophilia [10]. Skin findings distinguishing it from AD include a distinctive thickened texture of the facial skin, retroauricular fissures, and severe folliculitis of the axillae and groin [5]. Serum IgE levels are often >2000 IU/mL, and eosinophilia levels are often >700 cells/mL (eosinophilia does not correlate with the elevation in IgE), but patients usually do not suffer from symptomatic allergic disease such as AR, FA, or anaphylaxis [10,28]. Disturbances in the inflammatory process, and associated immune regulatory defects, are present. In clinical practice, a lower limit of 2000 IU/mL is often considered as a cutoff for AD-HIES. However, patients with HIES with lower IgE levels and STAT3 pathogenic variants have been reported [29]. Moreover, the serum IgE level does not correlate with
the severity and activity of the disease, and paradoxically patients with STAT3 loss-of-function (LOF) mutations are rather protected from severe allergic reactions. A potential explanation of this protection is disturbed mast cell degranulation, as well as vascular reaction to histamine caused by the STAT3 mutation itself [8,30–32]. SPT results and clinical symptoms of allergy are consistent with the specific IgE (sIgE) results in AD-HIES. Both skin and blood test results are comparable between patients with AD-HIES and healthy controls [32]. Defective neutrophil chemotaxis has been described among AD-HIES patients, and variable specific antibody production is seen [5,33]. Patients may require immunoglobulin replacement.

At the end of 20th century, the National Institutes of Health HIES scoring system was originally presented where a score of 30 has a sensitivity of 87.5 percent and a specificity of 80.6 percent [34]. It is noteworthy that some patients (e.g., some young children), may not meet the scoring criteria. Thereupon, in cases of positive family history of HIES and some distinctive features, according to experts, molecular screening should still be performed even if the score is below 30. Other diagnostic guidelines takes into account five cardinal clinical features (recurrent pneumonia, newborn rash, pathologic bone fractures, characteristic facies, and high palate) with total IgE level and Th17 cell count [35]. Molecular genetic testing is crucial to establish the diagnosis of the AD-HIES.

Autosomal-recessive-HIES (AR-HIES) is characterized by highly elevated serum levels of IgE, eczema, recurrent staphylococcal abscesses, and hypereosinophilia. In contrast to AD-HIES, where patients are usually free from allergic manifestations, 50% to 70% of patients with AR-HIES suffer from severe allergies, i.e., eczema, anaphylaxis to food, and environmental allergies, and 30% have asthma [10,32]. Pulmonary disease is usually asthma-related as compared with AD-HIES, with pneumatocele and lung damage due to prior infections [10].

Some patients with DOCK8 or TYK2 deficiency were previously classified as AR-HIES with harmful allergic symptoms [36]. Now, we better recognize the differences in the clinical features. DOCK8 deficiency is a combined immunodeficiency characterized by allergic inflammation, severe atopy, high IgE, susceptibility towards cutaneous viral infections, and malignancy [37]. TYK2 deficiency is also a combined immunodeficiency with recurrent skin viral infections, while eczema and elevated IgE are variably found. A study conducted by Boos et al. revealed that total serum IgE levels similarly increased in STAT3-HIES, DOCK8 deficiency, and AD patients. The ratio of aeroallergen-specific IgE to total IgE was the highest in AD, whereas patients with DOCK8 deficiency showed the highest specific serum IgE against food allergens. Th2-cell numbers were significantly increased in DOCK8 deficiency and AD patients compared to STAT3-HIES patients and controls. The study showed that hyper-IgE syndromes and atopic dermatitis patients showed a different sensitization pattern of serum IgE corresponding to the allergic disease manifestations and Th-cell subset data, suggesting a key role of DOCK8 in the development of FA [32]. Moreover, according to Wilkie et al., defective Treg function may contribute to the increased skin inflammation and the eczema in DOCK8 deficient patients [38]. IEI with elevated IgE are summarized in Table 1.
Table 1. Inborn errors of immunity with elevated IgE.

| Disease | IUIS Classification | Inheritance | Mutation | Characteristics | Immunological Features |
|---------|---------------------|-------------|----------|-----------------|------------------------|
| Hyper IgE syndrome (HIES) | Combined immunodeficiencies with associated syndromic features | AD LOF | STAT3 | Infectious disease and immunological manifestations (skin abscesses, recurrent sinopulmonary infections, bacterial infections, pulmonary aspergillus, Pneumocystis jirovecii, and chronic mucocutaneous candidiasis) Craniofacial, dental, musculoskeletal, neurological, and vascular abnormalities | Eosinophilia ↑ IgE ↓ specific antibody production Intermittent chemotactic defects Impaired inflammatory cytokine production Reduced or absent Th17 cells Decreased IFN-γ production upon stimulation Decreased CDS+ memory T cells Diminished delayed-type hypersensitivity and lymphoproliferative responses to antigenic stimulation |
| ZNF341 deficiency (phenocopy of AD-HIES) | Combined immunodeficiencies with associated syndromic features | AR | ZNF341 | Recurrent bacterial infections (respiratory, skin infections) Lung abscesses and pneumatoceles Musculoskeletal abnormalities Retention of primary teeth | ↑ IgE- and IgG specific antibody production ↓ memory B cells excess of Th2 cells ↓ Th17 and NK cells |
| Loeys–Dietz syndrome (TGFBR deficiency) | Combined immunodeficiencies with associated syndromic features | AD | TGFBR1TGFBR2 | Recurrent respiratory infections Eczema Food allergy Musculoskeletal abnormalities Retention of primary teeth Vascular abnormalities | ↑ IgE |
| PGM3 deficiency | Combined immunodeficiencies with associated syndromic features | AR | PGM3 | Impaired immunity (recurrent respiratory tract infections, abscesses) Severe atopy, asthma, eczema, and food allergy Autoimmunity Neurocognitive impairment Skeletal dysplasia | Neutropenia T and B cell lymphopenia Eosinophilia ↑ IgE levels N/↑ IgG and IgA Progressive bone marrow failure |
| Comel–Netherton syndrome | Combined immunodeficiencies with associated syndromic features | AR | SPINK5 | Congenital ichthyosis Bamboo hair Recurrent bacterial infections Atopy Failure to thrive | ↑ IgE and IgA ↓ switched and non-switched B cells |
| CARD11 deficiency | Combined immunodeficiencies with associated syndromic features | AD LOF | CARD11 | Severe atopic dermatitis Food allergy Molluscum contagiosum infection Recurrent respiratory infections Lymphoma Various phenotypes from SCID to combined immunodeficiency, associated with atopy and elevated IgE levels or isolated severe atopy | ↑ IgE Poor specific antibody production Impaired activation of both NF-κB and mTORC1 pathways N/↓ B cell numbers Defective T-cell activation and proliferation Skewing toward Th2 |
| ERBIN deficiency | Combined immunodeficiencies with associated syndromic features | AD | ERBB2IP | Recurrent respiratory infections Susceptibility to S. aureus Eczema Atopy Joint hypermobility, sometimes vascular abnormalities | ↑ IgE ↑ circulating Treg |
| Disease | IUIS Classification | Inheritance | Mutation | Characteristics | Immunological Features |
|---------|---------------------|-------------|----------|----------------|-----------------------|
| IL6R deficiency | Combined immunodeficiencies with associated syndromic features | AR | IL6R | Immune deficiency (recurrent pyogenic infections, cold abscesses) | High circulating IL-6 levels, Normal ↓ serum IgM, IgG, and IgA, Very ↑ IgE, Abnormal inflammatory responses |
| Interleukin 6 signal transducer (IL6ST) deficiency | Combined immunodeficiencies with associated syndromic features | AR | IL6ST | Recurrent infections | Recurrent viral and bacterial infections, Cutaneous infections (staphylococcal, viral, and fungal) |
| DOCK8 deficiency | Immunodeficiencies affecting cellular and humoral immunity | AR | DOCK8 | Susceptibility to intracellular bacteria (mycobacteria, Salmonella) and viruses | Susceptibility to intracellular bacteria (mycobacteria, Salmonella) and viruses |
| TYK2 deficiency | Defects in intrinsic and innate immunity | AR | TYK2 | Susceptibility to intracellular bacteria (mycobacteria, Salmonella) and viruses | Susceptibility to intracellular bacteria (mycobacteria, Salmonella) and viruses |
| Omenn syndrome (OS) | Immunodeficiencies affecting cellular and humoral immunity (usually a T-B-NK+ SCID) | AR | various | Susceptibility to intracellular bacteria (mycobacteria, Salmonella) and viruses | Susceptibility to intracellular bacteria (mycobacteria, Salmonella) and viruses |
| Wiscott–Aldrich syndrome (WAS) | Combined immunodeficiencies with associated syndromic features | XL | WAS | Recurrent bacterial and viral infections | Recurrent bacterial and viral infections, Bloody diarrhea |

Eosinophilia ↑ IgE, Specific antibody production variably affected, Impaired B cell memory and acute-phase response ↓ Th17 cells

Eosinophilia ↓ T cell numbers (with normal CD4/CD8 ratio) and variably decreased or normal B- and NK-cell numbers ↓ production of TNFα and IFNγ ↓ numbers of Th17 T cells ↑ Th 2 ↑ IL-4 and IL-13 Few Treg with poor function ↓ IgM levels and variable IgA and IgG levels ↑ IgE Poor antibody responses

Eosinophilia ↑ IgE, Abnormal secretion of IL-4 and IL-5 from activated T cells Exaggerated Th2 response Absence of B cells in the circulation

Eosinophilia ↓ IgM ↓ antibody responses to polysaccharides Progressive ↓ in T cells numbers

Abnormal lymphocyte responses to anti-CD3
**Table 1. Cont.**

| Disease                                                                 | IUIS Classification                                                                 | Inheritance | Mutation                                                                 | Characteristics                                                                 | Immunological Features                                                                 |
|------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Atypical DiGeorge syndrome with deletion of chromosome 22q11.2         | Combined immunodeficiencies with associated syndromic features                      | AD          | Deletion typically in chromosome 22                                     | Pharyngeal pouch defects, Thymus hypoplasia/aplasia, Hypoparathyroidism, Congenital heart disease, Eczema, erythroderma, Lymphadenopathy | Eosinophilia, ↑ IgE, Partial T cell deficiency, Oligoclonal T cells expansion, T cell count is higher than typical complete DiGeorge patients |
| IPEX syndrome (immunodysregulation, polyendocrinopathy, and enteropathy X-linked syndrome) | Diseases of immune dysregulation                                                    | XL          | FOXP3                                                                    | Multiple endocrinopathies, Severe chronic enteropathy, Dermatitis, Eczema, Anemia, Thrombocytopenia | ↑ IgE and IgA, Lack of (and/or impaired function of) CD4+ CD25+ FOXP3+ regulatory T cells (Tregs) |

Abbreviations: ↓—decreased; ↑—increased; γ—gamma; AD—autosomal dominant; AR—autosomal recessive; LOF—loss-of-function; N—normal; SCID—severe combined immunodeficiency; Treg—T regulatory cell; and XL—X-linked inheritance.
On the other hand, low levels of IgE interest immunologists. Selective IgE deficiency (defined as a significant decrease in the levels of IgE (<2.5 IU/mL) in patients whose other immunoglobulin levels, including IgG, IgG subclasses, and IgA levels, are normal) has not been included in international classification systems for IEI [1]. Low serum levels of IgE can be associated with some well-defined IEI: common variable immunodeficiency (CVID), IgG subclass deficiencies, slgAD, ataxia-telangiectasia (A-T), and agammaglobulinemia [39–41]. According to studies, an undetectable serum IgE (<2 IU/mL) occurs in only 3.3% of the general population [21]. In contrast, Lawrence et al. found that an undetectable IgE occurs in 75.6% of patients with CVID [21]. Another finding was a significant correlation between serum IgE with serum IgG, suggesting that lower IgE occurs in patients with more severe hypogammaglobulinemia. Moreover, false-negative results may appear using traditional methods of sIgE measurement, and allergen sIgE was not detectable in 96.5% of patients with CVID. Many patients with CVID report symptoms of rhinitis, wheeze, or adverse reactions to antibiotics, but it is difficult to detect allergic sensitization among them, especially using SPT or serum sIgE [41–43]. In these cases, sensitization should be confirmed using different methods, for example, an oral provocation challenge, and bronchial provocation tests with allergens [41]. The interpretation of food-specific IgE values and their usefulness in predicting symptomatic food allergies in the context of IEI patients is a potential field for further studies.

While diagnostics among PID patients during Ig replacement therapy (IRT) are often challenging, in the context of allergy, studies suggest that current Ig products are not a significant source of IgE [21].

3. Autoimmunity

There is also a high degree of overlap between autoimmune diseases and IEI in the context of genetic linkages and causes [44]. The molecular mechanisms responsible for the immune dysregulation in patients with IEI still are not fully recognized [45]. The usage of genetic analysis and a better understanding of the involved immune regulatory and signaling mechanisms is revealing the complex relationships between IEI syndromes and autoimmune diseases [44]. In the past, IEI and autoimmune diseases were considered as opposites; now, we know that genetic mutations may affect multiple immune cells and molecules, and in consequence IEI does not exclude autoimmunity. Furthermore, autoimmune diseases often coexist with some IEI [46].

The potential mechanisms associated with the pathogenesis of autoimmunity include impaired B cell differentiation and germ-center reactions, altered T cell central or peripheral tolerance, uncontrolled lymphocyte proliferation and differentiation, disturbances in Treg/Th17 balance, dysfunctional complement and innate immune activation, and the defective clearance of the infectious agents [45,46].

A French national study by Fischer et al. includes all types of IEI and autoimmune manifestations. The study demonstrated that autoimmunity is a significant component of clinical presentation of all types of IEI: one or more autoimmune and inflammatory manifestations were noted in 26.2% of 2183 retrospectively screened IEI patients, with a risk of onset throughout the patient’s lifetime. The risk of autoimmune cytopenia (AIC) was at least 120 times higher than in the general population; among children the risk of inflammatory bowel disease (IBD) was 80 times higher, while the risk of arthritis was 40 times higher. The risk of other autoimmune complications was approximately 10 times higher. Autoimmune manifestations occurred in patients with all types of IEI; however, patients with T-cell defects or CVID had, statistically speaking, the highest risk for autoimmunity [47].

The signs and symptoms of most rheumatic diseases are classified in international American College of Rheumatology (ACR) or European League Against Rheumatism (EULAR) criteria. The management of autoimmunity in patients with IEI is often challenging because immune dysregulation, as well as permanent inflammation, may influence the diagnostic process. Moreover, when assessing a patient with IEI for possible autoimmunity, it is important to consider a broad differential diagnosis, because infectious diseases, adverse
effects of medications, and malignancies can mimic autoimmune processes. Thereupon, a complete diagnostic process is not effortless and requires a history, a complete physical examination, wide laboratory testing, imaging, and even pathological investigations [48]. Clinicians must be aware of the characteristic clinical features of autoimmune diseases among IEI patients. These include polyautoimmunity, which is defined as the presence of more than one autoimmune disease in a single patient and early onset autoimmunity (the presence of autoimmune disease at any age that is earlier than usual) [46]. Some IEI are associated with specific autoimmune diseases, and the awareness of these patterns also allows clinicians to monitor patients more effectively.

During evaluation of a patient with IEI and suspected autoimmunity, some laboratory tests are needed. This includes a complete blood count with differential, acute phase reactants, autoantibodies, serologies, flow cytometry, cytokine analysis, levels of complement, human leukocyte antigen (HLA) typing, and comprehensive endocrine and/or metabolic panels [48].

On the other hand, laboratory tests may help to catch patients with IEI among heterogeneous group of patients with already diagnosed autoimmunity. Immune phenotyping and immunoglobulin (Ig) levels are indispensable. The ratio of naïve and memory T cells (CD45RA/CD45RO) may differentiate patients with late-onset or profound combined immunodeficiency disorders [49–52].

In addition, specific subsets of T and B cells have been linked to IEI with autoimmunity. These include the expansion of TCRαβ CD4−CD8− (double-negative) T cells in autoimmune lymphoproliferative syndrome (ALPS), CD19hi21lo B cells in CVID with autoimmunity, an abnormal count of Treg in Tregopathies, Th17 cells in STAT1 GOF patients, and expanding follicular helper T cells (Tfh) in CTLA4 and LRBA deficiency. Changes in these subsets may also predict the progression of autoimmune complications or a response to therapy [52,53].

Primary antibody deficiencies (PADs) are the most common inherited IEI in humans, with recurrent infections as a predominant presenting complaint. However, various types of PADs are also associated with inflammatory disorders, granulomatous lesions, lymphoproliferative diseases, and cancer. Several studies have reported that PAD patients are predisposed to autoimmune complications [47,54].

X-linked agammaglobulinemia (XLA), also known as Bruton agammaglobulinemia, is the prototype antibody deficiency [55]. Function-loss mutations in Bruton’s tyrosine kinase (BTK) lead to a block in B-cell maturation, a near total absence of B cells in the periphery, and severe reductions in serum immunoglobulins. Surprisingly, most patients with XLA have a small number of B cells, or “leaky B cells”, in the peripheral blood [54,56]. Patients with XLA are rather at a low risk of autoimmune or inflammatory diseases compared with other IEI patients, but several studies suggest that some XLA patients show symptoms with similar diagnostic features to rheumatoid arthritis (RA), IBD, alopecia, enteropathy, autoimmune hemolytic anemia (AIHA), immune thrombocytopenic purpura (ITP), neutropenia, and Kawasaki disease [54,57–59]. These patients are not expected to produce autoantibodies; however, surprisingly, the “leaky” production of autoantibodies and defects in B-cell central tolerance has been reported [54,60,61].

Autoimmune diseases occur in 20–30% of CVID patients. The most reportable are autoimmune cytopenias such as ITP, AIHA, and Evans syndrome; however, organ-specific and systemic autoimmune diseases are also described [45,62–64].

It is worth mentioning that it is not uncommon that autoimmune complications are the first or the only clinical manifestation of CVID during diagnostics [54,65].

A cohort study on CVID patients with immune cytopenia showed higher levels of serum immunoglobulin, CD19hi B cells, and T CD4 effector T cells, accompanied by reduced naïve T cells [45,66]. Moreover, according to several studies, Treg frequency and their functional characteristics are disturbed in CVID patients [54,67–69], which may result in elevated levels of activated T cells; autoimmunity; and chronic inflammation. Defects in Tregs are also correlated with the expansion of CD21low B cells in CVID patients with
In a study by Boileau et al., the serum IgG level in CVID patients with autoimmunity (cytopenia and others) was greater than in CVID patients without autoimmunity [66]. Other studies revealed that CVID patients with autoimmunity have higher levels of IgM compared with non-autoimmune phenotypes [73,74]. On the other hand, markedly depressed serum immunoglobulin levels have been reported in patients with RA, Sjögren’s syndrome (SS), and systemic lupus erythematosus (SLE), prompting suspicion of IEI [75,76].

Autoantibodies circulating in the serum and/or plasma, as well as the immune complex deposits containing autoantibodies and complement, are essential diagnostic tools in most autoimmune diseases. In patients with hypogammaglobulinemia (i.e., CVID, XLA etc.) and some types of CIDs, diagnostic tests that are based on antibodies may be not useful and provide false-negative results. For example, the diagnosis of definite autoimmune hepatitis (AIH) in CVID patients is definitely challenging. According to the European Association for the Study of the Liver (EASL), both histologic evidence of moderate to severe interface hepatitis and the positivity of the typical autoantibodies are required to make an AIH diagnosis [77,78]. It is not surprising that CVID patients generally may not have autoantibodies, even in the case of noticeable autoimmune complications.

However, in a study by Tahiat et al. among 299 IEI patients with a dominance of PAD (27.8%) and CID (26.1%), autoantibodies were found in 32.4% of all IEI patients, compared with 15.8% of healthy subjects. Anti-nuclear antibodies (ANA) (10.0%), transglutaminase antibody (TGA) (8.4%), RBC antibodies (6.7%), anti-smooth muscle antibody (ASMA) (5.4%), and ASCA (5.0%) were the most common autoantibodies. The authors have concluded that considering the association of some autoimmune diseases with certain PIDs, screening for corresponding autoantibodies would be recommended. However, due to the low positive predictive value of the autoantibodies, the results should be interpreted with caution in patients with IEI [79].

Oppositely, the production of specific antibodies may be impaired even when the level of main classes of immunoglobulins is normal in specific antibody deficiency (SAD). Consequently, most autoantibodies are not found in these patients [48,80,81]. In slgAD, as well as in CVID with IgA deficiency, it is obvious that there is a lack of antibodies in this immunoglobulin class (for example, tissue transglutaminase IgA–tTg IgA). On the other hand, among patients during IRT, exogenous Ig may interfere with some of the special immunologic tests. That is why it is worth considering if some screening tests such as autoantibodies should be performed before the therapy is being initiated or the serum should be frozen for future testing [48].

Some IEI patients are constantly negative for disease-specific autoantibodies, and in the case of clinical suspicion of autoimmune disease, other diagnostic methods should be considered. Medical imaging is often a part of the clinical evaluation of patients with suspected autoimmune disorder. In the case of IEI patients, some difficulties may appear at this point too. In particular types of IEI there is a problem with radiosensitivity, which limits the use of medical radiation for the diagnosis of autoimmunity [82–84]. Genetic instability, defective DNA repair, and a predisposition to malignancy are associated with specific types of IEI. A-T and NBS are well-defined IEI connected with defective DNA repair [85], where patients might be sensitive to radiation. X-ray exposure should be limited to diagnostic purposes only when it is medically necessary because patients should be protected from unnecessary medical techniques that incorporate radiation. Substitution with magnetic resonance imaging (MRI) or ultrasound is desirable [48].

Histopathological examination is sometimes crucial and clinically indicated in a diagnostic process. Diagnostic challenges may occur here as well. In IEI patients, as an effect of immunoglobulins and immune cells deficiency, affected tissue can have a different histological appearance in comparison to healthy individuals [48,78,86–88].

Since autoimmune cytopenia (AIC) is a common finding in IEI patients, Westermann-Clark et al. evaluated 154 pediatric patients with AIC in the context of IEI. Splenomegaly, short stature, and recurrent or chronic infections were common clinical features among
patients with AIC and IEI. IEI patients were more likely to have AIHA or Evans syndrome than AIC-only patients. Patients with both IEI and AIC more often had low CD3 and CD8 cells; low IgA and IgG levels; and a higher prevalence of autoantibodies to red blood cells, platelets, or neutrophils. AIC diagnosis preceded IEI diagnosis by 3 years on average, except among those with partial DiGeorge syndrome [89]. The early detection of patients with comorbid IEI and AIC may improve treatment outcomes.

The main molecular defects and common autoimmune complications among IEI are summarized in Table 2.

Table 2. Common autoimmune presentation in inborn errors of immunity (IEI).

| IU5S Classification | Disease | Main Molecular Defect | Common Autoimmune Disease |
|---------------------|---------|-----------------------|---------------------------|
| Immunodeficiencies affecting cellular and humoral immunity | ICOS deficiency | ICOS | Arthritis, SLE, MS, and enteropathy |
| Combined immunodeficiencies with associated syndromic features | 22q11 deletion syndrome (DiGeorge syndrome) | Large deletion typically in chromosome 22 | AIC, AIT, and arthritis |
| | Wiskott–Aldrich syndrome | WAS | AIC, IB, GN, arthritis, and vasculitis |
| Predominantly antibody deficiencies | X-linked agammaglobulinemia | Btk | RA, JIA, IB, AIC, AIT, PND, KD, DM, T1D, SD, and alopecia |
| | CVID | Various | AIC (ITP, AIHA, AN), RA, JIA, SLE, IB, AIT, PA, SS, and vitiligo |
| | Selective IgA deficiency | Unknown | AIC (ITP, AIHA), IB, CD, PV, MG, SLE, RA, JIA, T1D, and AIT |
| | P110 delta deficiency | PIK3CD | IB, AIC |
| | Hyper IgM syndrome | CD40, CD40L | AIT, IB, RA, JIA, AIHA, and AGN |
| | LRBA deficiency | LRBA | AIC (AIHA, ITP, AN), IB, RA, and JIA |
| | APECED | AIRE | T1D, AD, AIT, hypoparathyroidism, enteropathy, adrenal corticotropic hormone insufficiency, growth hormone insufficiency, vitiligo, alopecia, autoimmune hepatitis, and ovarian/testicular failure |
| | IPEX | FOXP3 | IBD, AIC, AIT, vitiligo, alopecia, hepatitis, and early onset diabetes |
| | CTLA4 haploinsufficiency | CTLA4 | IBD, AIC, SLE, and arthritis |
| | XIAP deficiency | XIAP | IB, AIC, and hepatitis |
| Diseases of immune dysregulation | Early onset inflammatory bowel disease syndromes | various | IBD, arthritis |
| | STAT3 GOF | STAT3 | IBD, AIC, hepatitis, and early-onset T1D |
| | ALPS | various | AIC, GN, endocrinopathies, and SLE |
| Congenital defects of phagocyte number, function, or both | Chronic granulomatous disease | CYBB | IBD, AIC, AIT, JIA, GN, SLE, APLA, and autoimmune pulmonary disease |
| Defects in innate immunity | STAT1 deficiency | STAT1 GOF | AIC, AIT, T1D, and SLE |
| Autoinflammatory disorders | Type 1 interferonopathies | various | SLE, AIC, and vasculopathy |
| Complement deficiencies | Complement deficiencies | various | SLE, vasculitis |

Abbreviations: AD—Addison’s disease; AIC—autoimmune cytopenia; AIHA—autoimmune hemolytic anemia; AIT—autoimmune thyroid disease; AN—autoimmune neutropenia; ALPS—autoimmune lymphoproliferative syndrome; APECED—autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; APLA—antiphospholipid antibodies; CD—celiac disease; CVID—common variable immunodeficiency; GN—glomerulonephritis; GOF—gain-of-function; IB—chronic inflammatory bowel disease; IU5S—International Union of Immunological Societies; JIA—juvenile idiopathic arthritis; IPEX—immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome; ITP—immune thrombocytopenia; MS—multiple sclerosis; RA—rheumatoid arthritis; SLE—systemic lupus erythematosus; and T1D—type 1 diabetes.

4. Non-Malignant Lymphoproliferation

Ranging from reactive polyclonal hyperplasia (associated with immune disorders) to true monoclonal disease (malignant process), lymphoproliferative disorders (LPDs)
constitute a heterogeneous group of diseases in clinical and genetic terms. LPDs occur when the physiological control of proliferation of both T and B cells collapses. Disturbances in this control may occur in many conditions where immunity is compromised. This creates difficulties (both in the clinical assessment of the patient and in the identification of pathogenic mechanisms) to differentiate LPDs [90]. They are observed in patients with immunodeficiency or immune dysregulation syndromes such as CVID, SCID, WAS, A-T, Chediak-Higashi syndrome (CHS), and X-linked lymphoproliferative disorders [91]. Additionally, splenomegaly and/or generalized lymphadenopathy are described in disorders such as CD27 deficiency, CD70, ITK deficiency, and XLP type 1. Autoimmune disorders, hypersensitivity reactions, and viral infections, including human immunodeficiency virus (HIV) infection, are also prone to developing lymphoproliferative disorders. Lymphoproliferation as well as lymphomas (both Hodgkin’s and non-Hodgkin’s lymphomas) are often associated with Epstein–Barr virus (EBV) infection. Moreover, both lymphadenopathy and splenomegaly can be caused by nonspecific infections, in CVID but also in almost any other PID, and they are not always primarily associated with immune dysregulation [92]. Transplant patients, as well as those taking immunosuppressants such as cyclosporine, sirolimus, and tacrolimus, are also at risk of developing benign LPDs [93].

Autoimmune lymphoproliferative syndrome (ALPS) is an example of a disease resulting from impaired apoptosis of lymphocytes, mostly as a consequence of abnormalities associated with programmed cell death mediated by Fas. Fas is a transmembrane receptor located on the cell surface and is one of the tumor necrosis factor receptors (TNFR). It is responsible for the induction of apoptosis, which is triggered after binding with the appropriate ligand (FasL). When the \textit{FAS} gene is mutated, there are defects in the external pathway of programmed cell death [94]. Clinically, patients develop chronic lymphoproliferation and an increased number of T cells, which are referred to as “double negative T cells” (DNT) with CD4\(^-\)/CD8\(^-\), CD3\(^+\), and TCR\(\alpha\beta\)\(^+\) phenotype [95].

ALPS usually presents in infancy or early childhood (the median age is 31–36 months), most often in the form of nonmalignant lymphoid expansion with lymphadenopathy, splenomegaly, and/or hepatomegaly and AIC, including hemolytic anemia and thrombocytopenia. In a minority of patients, clinical symptoms may appear later in life (18 to 35 years). In a French cohort, patients with later disease onset often presented autoimmune manifestations rather than LPD [96,97]. Patients often do not present symptoms that would suggest an infectious or neoplastic etiology. Most patients have an increased number of T and B lymphocytes, as well as polyclonal hypergammaglobulinemia. Hypogammaglobulinemia, often not associated with increased susceptibility to infections, may occur in approximately 10% of cases. Autoimmunity is a common feature of ALPS and can be the first ALPS manifestation; however, it is not always present at the time of diagnosis. Autoantibodies are detected in up to 80% of patients, most often anticardiolipin antibodies or direct Coombs’ antibodies, but only half of them actually have an autoimmune disease, usually AIHA, ITP, or autoimmune neutropenia (AIN). A pledge of hemolysis during examination of blood smears, as well as the detection of autoantibodies and a degree of reticulocytosis, are helpful in distinguishing AIC from the effects of coexistent hypersplenism. Another helpful diagnostic tip is that AIC often manifests clinically. Autoantibodies typically have high affinity and are IgG-derived, in contrast to naturally occurring autoantibodies of the same specificity that are low-affinity and IgM-derived. Autoimmune diseases that affect other systems than the haematopoietic system can also occur but are much rarer [98]. Regardless of the time since the disease onset, symptoms such as lymphadenopathy and/or splenomegaly will ultimately be seen in 100% of ALPS patients and are required for diagnosis. The areas most commonly affected by lymphadenopathy are the neck, mediastinum, armpits, groin, and pelvis, although virtually any lymph node can become enlarged. Lymphoproliferation tends to subside over time, and by the age of 20, as much as 66% of patients achieve complete remission, while the rest of the patients experience a significant improvement. Infections are sporadic but can also occur as a result of neutropenia and/or nasopharyngeal obstruction due to lymphadenopathy [99]. Moreover, patients with ALPS
are characterized by an increased risk of cancer (estimated at 10–20%); the most common forms of cancer are Hodgkin’s lymphoma and non-Hodgkin’s lymphoma [100].

Lymphoma can develop at any age in ALPS–FAS but is rare as a presenting feature. Distinguishing a benign node from a questionable node is a diagnostic challenge because of the frequent concomitant presence of benign/typical lymphadenopathy and splenomegaly seen with ALPS. Important clues for lymphoma are classic alarm symptoms (B symptoms), including fever, night sweats, itching, and weight loss. Positron emission tomography (PET)-based imaging may be helpful for distinguishing “good” from “bad” nodes on the basis of the presumed higher metabolic activity of malignant lymphoid tissue [101]. The nonmalignant lymphadenopathy fluctuates, and PET scan results fluctuate similarly. Lymphoma nodes more often are continuously chemically active (“hot”). Lymphoma typically originates in the B cell lineage, but T cell lymphomas have also occurred.

The required criteria for the diagnosis of ALPS include chronic lymphoproliferation lasting more than 6 months with the exclusion of neoplastic and infectious lymphoproliferation. In isolated lymphadenopathy, they must involve two distinct nodal regions. The second of the required criteria includes elevated counts of double negative T cells in peripheral blood that exceed 1.5% of the total number of lymphocytes or 2.5% in the case of T lymphocytes [102]. In addition, the diagnostics include genetic, biochemical (increased concentration of vitamin B12/IL-10/IL-18/sFASL/FAS), and histopathological tests.

5. Neoplastic Manifestations

Along with a predisposition to severe and recurrent infections and autoimmunity, neoplasms form a triad that identifies the most common symptoms in a variety of IEI. Despite this, there is a lack of systematic data on the cancer risk and type of neoplasms seen in most IEI. The development of malignant neoplasms most often occurs in patients with CVID, and in patients with defects in genes regulating DNA repair, cell cycle, apoptosis, or bone marrow maturation. Available population cohort studies suggest that the increased risk of developing cancer is limited to specific and rare forms of IEI and is mainly due to an increased risk of developing lymphoma [103–106]. The highest risk of lymphomas was reported in NBS (49%), X-linked lymphoproliferative syndrome (XLP; 24–30%), A-T (15–19%), ALPS (7–15%), and the mentioned CVID (1.8–8.2%) [96,103,107,108]. Among CVID patients, there is a 7- to 10-fold increase in gastric cancer incidence, which is related to the lack of secretory IgA [109,110]. In patients with CVID, extra-nodal non-Hodgkin’s B-cell lymphomas and mucosa-associated lymphomas are the most common [111]. Unlike most IEI, lymphomas in CVID are more common in people in the 4th to 7th decade of life and are usually EBV-negative [111,112]. In a study by Ludvigsson et al., individuals with IgA deficiency were at a moderately increased risk of cancer, with excess risks of gastrointestinal cancer. Children with IgA deficiency were at no increased risk of cancer, but the statistical power was limited in subanalyses [113].

Common high-grade DNA strand repair defects with chromosomal instability are seen in the A-T. Ruptures of dsDNA cause a high percentage of malignant tumors, chromosome instability, and abnormal rearrangements of V (D) J genes; a recombination of class switches and/or somatic hypermutations (the ATM gene in A-T, the NBN gene in NBS, the DCLRE1C gene in severe combined deficiency immunodeficiency with sensitivity to ionizing radiation and Omenn syndrome, the LIG4 gene in the LIG4 syndrome, and the LIG1 gene in DNA ligase 1 deficiency) cause complex immunodeficiencies and malignant neoplasms, most often lymphomas [114,115]. Patients with Bloom’s syndrome (BLM gene) age prematurely and are susceptible to non-Hodgkin’s lymphoma (NHL). Patients with Schimke syndrome (SMARCAL1 gene) show chromosomal instability and an increased risk of malignant neoplasm, including NHL and osteosarcoma [116,117].

Malignancies associated with impaired telomere maintenance are observed in genetically heterogeneous congenital dyskeratosis and its clinically severe variant of Hoyeraal Hreidarsson syndrome, NBS and A-T. Disorders of telomerase lead to the defective function of rapidly dividing cells and increased susceptibility to hematological and solid tumors [114].
IEI, which inherently affect hematopoiesis, make it susceptible to malignant neoplasms. In Fanconi anemia, a genetically heterogeneous disorder, pancytopenia, hematologic malignancies, solid tumors, and clinical immunodeficiency phenotypes are observed. Mutations of the WAS gene coding for the WASP disrupt the connection between GTPases and the actin cytoskeleton, thus disrupting the regulation of signaling in hematopoietic cells. Myelodysplasia, leukemias, and lymphomas in patients with WAS are seen more frequently [107,114,118]. The deficiency of the hematologic transcription factor GATA2 leads to phenotypically variable immunodeficiency, primary alveolar proteinosis, Emberger syndrome with lymphedema and/or a predisposition to myelodysplastic syndrome, acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and EBV lymphoma [119]. The risk of leukemia is increased with some severe congenital neutropenia (ELANE, HAX1, and WASP) but not increased with the ELANE mutation that causes cyclic neutropenia. An increased risk of leukemia has not been reported in other PIDs associated with neutropenia [120]. Mutations in the CD40L gene cause X-linked immunodeficiency with hyperimmunoglobulin M. In the case of CD40L and CD40 ligand deficiencies, a Cryptosporidium biliary tract infection may lead to sclerosing cholangitis, cirrhosis, and an increased risk of hepatocellular carcinoma and biliary tract cancer [121–123].

Almost 20% of all human malignancies are associated with chronic infections with such pathogens as HBV, HCV, HPV, EBV, HHV8/KSHV, HTLV-I, HIV-1, HIV-2, JCV, Merkel cell carcinoma (MVC), Helicobacter pylori, schistosomes, or hepatic flukes [124,125]. Additionally, in IEI patients, chronic infections are often associated with malignancies. They were mostly described in connection with EBV, HPV, and HHV8 infections [107,126–128]. HPV can cause cancer of the cervix, vagina, vulva, anus, and penis, as well as squamous cell carcinoma of the oral cavity. Patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome are particularly prone to HPV infection, resulting in numerous warts, condylomata acuminate, and subsequent severe papillomatosis and malignant transformation of the lesions [128].

EBV in patients with IEI may cause chronic EBV viremia, hemophagocytic lymphohistiocytosis (HLH), dysgammaglobulinemia, atypical EBV-associated lymphoproliferative disorders (polymorphic B-cell hyperplasia, plasmocytic hyperplasia), and EBV-associated lymphomas [105,129,130]. In the rare heterogeneous KID syndrome (keratitis, ichthyosis, and deafness), mainly caused by mutations in the connexin 26 (GJB2) gene, 15% of patients develop squamous cell carcinoma, often in sun-exposed areas [131,132].

The estimated risk for developing cancer in patients with IEI ranges from 4 to 25 percent [133]. Furthermore, the diagnosis of the malignancy, both clinical and histological, can be challenging in the presence of non-malignant lymphoproliferation or bone marrow abnormalities. These states, as well as concomitant infections or complex co-morbidities, all can mimic a developing malignancy clinically, radiologically, and even histopathologically. Due to the statistically higher risk of the above-mentioned types of neoplasms, patients with IEI should undergo periodic age-appropriate screening tests, just like healthy people. However, the guidelines in this regard may differ depending on the IEI type and national or international recommendations. Patients with epidermodysplasia verruciformis (EV) should undergo regular dermatological check-ups due to an increased risk of skin cancer. Patients with A-T and their female family members with heterozygous mutant ATM should start the screening for breast cancer earlier than the general population, and this age depends on the type of the mutation in the ATM gene [134,135].

It is also worth mentioning that both NHL and Hodgkin lymphoma are diagnosed at younger ages in patients with IEI, and NHL is more common in males with IEI [136,137]. In patients with suspected lymphoma, medical management is the same as in immunocompetent patients; however, diagnostic difficulties may appear. Diagnostic tests useful in cancer screening include uric acid, lactate dehydrogenase (LDH), and erythrocyte sedimentation rate (ESR). Even histopathology, which is a gold standard of diagnosing malignancy, can be challenging in patients with IEI, particularly during the investigation of possible lymphoid malignancy.
If clinically indicated, a surgical biopsy providing sufficient material for the assessment of tissue architecture and ancillary diagnostic techniques is a better diagnostic option than needle core biopsy. Histological diagnosis may be difficult even when appropriate, high-quality material is gained [137,138]. For example, non-malignant lymphoproliferative lesions may precede, as well as co-exist with, lymphoid malignancies. Often, diagnostic boundaries between non-neoplastic and neoplastic lesions are ill-defined and difficult to apply. Lymphocyte clonality assessed by molecular techniques may help during diagnostics, but these alone cannot provide diagnostic certainty, and clonal B-cell and T-cell proliferations falling short of malignancy are not uncommon in IEI [138,139].

Patients with specific immunodeficiencies, including A-T, NBS, and CVID, should be informed about the increased risk of neoplasia associated with increased sensitivity to ionizing radiation. Before performing tests or therapy with the use of radiation, they should consult this fact with the attending immunologist. On the other hand, medical personnel should consider the benefit–risk ratio in terms of interventions with the use of ionizing radiation in the context of the underlying disease, taking into account the need to perform the examination, and the possibility of replacing the examination with radiation with alternative techniques without the use of ionizing radiation.

Advances in the diagnosis and treatment of patients with IEI contributed to a significant extension of the life of those patients who previously had no chance to live to adulthood. Patients with IEI require multidisciplinary care; therefore, physicians of various specialties should be aware of the increased tendency to develop neoplasms in these patients. Patients should be thoroughly informed about the alarm symptoms of malignant neoplasms, especially lymphoma. Cancer in a patient with IEI is more often extensive or disseminated at the time of diagnosis, which is associated with a worse prognosis. Patients with IEI are more likely to develop NHL with B-cell origin, with high histologic grades and extranodal involvement, especially in the gastrointestinal tract or central nervous system. Early diagnosis can provide better treatment options before serious organ damage occurs.

The most prevalent types of malignancies among IEI patients have been summarized in Table 3.

**Table 3.** Most common types of cancer among patients with IEI.

| Disease                  | IUIS Classification                          | Type of Malignancy                          |
|--------------------------|----------------------------------------------|---------------------------------------------|
| SCID                     | Immunodeficiencies affecting cellular and humoral immunity (Ia) | Lymphoma                                   |
| ITK deficiency           | Immunodeficiencies affecting cellular and humoral immunity (lb) | EBV-associated lymphoproliferation, Lymphoma |
| IKAROS deficiency (CD154) | Immunodeficiencies affecting cellular and humoral immunity (lb) | T-ALL                                       |
| DOCK8 deficiency         | Immunodeficiencies affecting cellular and humoral immunity (lb) | Vulvar, facial, and anal squamous cell dysplasia and carcinomas, T cell lymphoma-leukemia, Burkitt lymphoma, NHL |
| STK4 deficiency          | Immunodeficiencies affecting cellular and humoral immunity (lb) | Lymphoma                                   |
| RHOH deficiency          | Immunodeficiencies affecting cellular and humoral immunity (lb) | Lymphoma                                   |
| OX40 deficiency          | Immunodeficiencies affecting cellular and humoral immunity (lb) | Kaposi sarcoma                             |
| CD40/CD40L deficiency    | Immunodeficiencies affecting cellular and humoral immunity (lb) | Hepatocarcinoma, Cholangiocarcinoma, Peripheral neuroectodermal tumors of the gastrointestinal tract and the pancreas, Lymphoma |
| Disease | IU5S Classification | Type of Malignancy |
|---------|---------------------|--------------------|
| Wiskott–Aldrich syndrome | Combined immunodeficiency of T and B cell with associated or syndromic features | Lymphoma, Leukemia, Cerebellar astrocytoma, Kaposi sarcoma, Smooth muscle tumors |
| Ataxia-telangiectasia | Combined immunodeficiency of T and B cell with associated or syndromic features | Leukemia, Lymphoma, Breast cancer, Gastrointestinal malignancies (possible) |
| Nijmegen breakage syndrome | Combined immunodeficiency of T and B cell with associated or syndromic features | Lymphoma, Acute leukemia, Solid tumors |
| Bloom syndrome | Combined immunodeficiency of T and B cell with associated or syndromic features | Leukemia, Lymphoma |
| PMS2 deficiency | Combined immunodeficiency of T and B cell with associated or syndromic features | Lymphoma, Colorectal carcinoma, Brain tumors |
| MCM4 deficiency | Combined immunodeficiency of T and B cell with associated or syndromic features | B cells lymphoma |
| Ligase I deficiency | Combined immunodeficiency of T and B cell with associated or syndromic features | Lymphoma |
| Cartilage-hair hypoplasia | Combined immunodeficiency of T and B cell with associated or syndromic features | Lymphoma, Leukemia, Squamous cell carcinoma, Basal cell carcinoma |
| Schimke syndrome | Combined immunodeficiency of T and B cell with associated or syndromic features | Osteosarcoma, NHL |
| Autosomal dominant hyper-IgE syndrome (AD-HIES) | Combined immunodeficiency of T and B cell with associated or syndromic features | NHL |
| CID with early-onset asthma, eczema and food allergies, autoimmunity ID with atopic dermatitis (CARD11) | Combined immunodeficiency of T and B cell with associated or syndromic features | Lymphoma |
| X-linked agammaglobulinemia | Predominantly antibody deficiencies | Lymphoreticular malignancies, Gastric and colorectal adenocarcinoma, Squamous cell carcinoma of the lung |
| Common variable immunodeficiency (CVID) | Predominantly antibody deficiencies | Lymphoma, Thymus cancer, Gastric cancer |
| Selective IgA deficiency | Predominantly antibody deficiencies | Gastrointestinal cancer |
| X-linked lymphoproliferative disease (XLP1) | Diseases of immune dysregulation | Lymphoma |
| CD27 deficiency | Diseases of immune dysregulation | Lymphoma |
| RASGRF1 deficiency | Diseases of immune dysregulation | EBV-associated lymphoma |
| CD70 deficiency | Diseases of immune dysregulation | Hodgkin lymphoma |
| CTPS1 deficiency | Diseases of immune dysregulation | B-cell NH lymphoma |
| CD137 deficiency | Diseases of immune dysregulation | B-cell lymphoma |
Table 3. Cont.

| Disease                                      | IUIS Classification                                      | Type of Malignancy  |
|----------------------------------------------|----------------------------------------------------------|---------------------|
| XL magnesium EBV and neoplasia (XMEN)        | Diseases of immune dysregulation                         | Lymphoma            |
| ALPS–FAS                                     | Diseases of immune dysregulation                         | Lymphoma            |
| Severe congenital neutropenia                | Congenital defects of phagocyte number, function, or both | MDS/leukemia        |
| HAX1 deficiency                              | Congenital defects of phagocyte number, function, or both | MDS/leukemia        |
| Shwachman-Diamond syndrome                   | Congenital defects of phagocyte number, function, or both | Leukemia            |
| GATA2 deficiency                             | Congenital defects of phagocyte number, function, or both | AML/CML             |
| WHIM syndrome                                | Defects in intrinsic and innate immunity                 | HPV-related cancers |
| Epidermodysplasia verruciformis              | Defects in intrinsic and innate immunity                 | Squamous cell carcinoma |

Abbreviations: AML—acute myelogenous leukemia; CMML—chronic myelomonocytic leukemia; EBV—Epstein–Barr virus; HPV—human papillomavirus; MDS—myelodysplastic syndrome; NHL—non-Hodgkin lymphoma; and T-ALL—T-cell acute lymphoblastic leukemia.

6. Diseases of Immune Dysregulation

Diseases of immune dysregulation are a separate and independent category of IEI in IUIS classification [1]. This category includes i.a. familial hemophagocytic lymphohistiocytosis (FHL syndromes), FHL syndromes with hypopigmentation, regulatory T cell defects, autoimmunity with or without lymphoproliferation, immune dysregulation with colitis, ALPS, and a susceptibility to EBV and lymphoproliferative conditions. This category is often the most difficult to define clinically and to diagnose without extensive sequencing since there is a significant phenotypic overlap between different genetic causes, the evolution of features over time, and phenotypic heterogeneity. On the other hand, these diseases have improved our understanding of the pathways that drive autoimmunity in IEI.

Early-onset autoimmunity, autoimmunity that involves multiple organs, a strong family history of autoimmunity, autoimmunity in combination with susceptibility to infection, or significant lymphoproliferation all suggest an immune dysregulation defect.

Diseases of immune dysregulation, according to IUIS classification, are summarized in Table S1.

Over the years, the wide application of whole-exome sequencing/whole-genome sequencing has significantly promoted the discovery and further study of new IEI and its number has doubled from 2009 to 2019 [1,140]. It is worth mentioning that the number of cases for any particular IEI is usually few, and because of that, a large-scale study of IEI can hardly be conducted [140]. Furthermore, there are several difficulties in identifying IEI connected with immune dysregulation. There are still countries where genetic tests are not widespread and freely available, mostly because of their costs. Moreover, in some patients more than one mutation is present, which makes it even more difficult to find [140,141]. In addition, phenotypes of the same mutation vary between patients, ranging from mild or uncharacteristic symptoms to even life-threatening manifestations [140,142,143]. In conclusion, patients with immune dysregulation should be examined scrupulously, and genetic diagnostics should be conducted in cases when it is necessary and possible [140].

Early and proper diagnosis seems crucial when we consider IEI patients. In cases of IEI patients with immune dysregulation, it is even more important.

The treatment is often challenging and sometimes requires balancing between increased susceptibility to infection and the additional suppression of the immune system [144]. Not so long ago, treatment options for IEI patients remained limited. They included the intensive treatment of infections; IRT; and bone marrow transplant in some cases. IRT has been a
standard, often live-saving treatment for IEI that has affected antibody production for the past four decades. Both intravenous (IVIg) and subcutaneous (SCIg) immunoglobulins are often suitable for lifelong therapy. High-dose IVIg, together with corticosteroids, is a standard therapy for ITP [144]. A significant increase in the field of clinical immunology, including molecular biology techniques, gene therapy, or the use of immune modulators, allowed the development of modern and precise therapies [145]. Equally, having better knowledge of IEI pathophysiology enables the implementation of targeted therapy. IEI is an excellent example of disease where such “precision medicine” can be applied. Precision medicine is an approach based on advances in genetic research and data analysis. It offers breakthroughs in the treatment of the disease and has the potential to overturn traditional methods of practicing medicine.

Such medicines (new or repurposed) modify intracellular pathways whose function is disturbed because of specific genetic defect [144]. Thanks to precision medicine, the treatment can selectively influence a specific cell function instead of affecting the entire immune system. Moreover, the adverse side effects that affect other tissues are possible to avoid.

Although the term “precision medicine” is relatively new, it has been part of healthcare for many years. For example, a person who needs a blood transfusion does not receive blood from a randomly selected donor; instead, the donor’s blood group is matched to that of the recipient to reduce the risk of complications. Precision medicine is already used in the treatment of diabetes and cancer. It is especially useful in cases of breast, lung, skin, colon, prostate, and pancreatic cancer. Its other promising applications include cardiology, signs of aging, rare childhood diseases, cystic fibrosis, and HIV.

In the context of immunedysregulation, the usage of small molecules and biologics effectively helps with reversing the clinical manifestations of immunedysregulation and hyperinflammation. Knowledge about the genetic etiology of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) allowed one to explore PI3Kδ inhibition as a precision medicine [146,147]. Leniolisib, a small-molecule, selective PI3Kδ inhibitor, causes the dose-dependent suppression of PI3Kδ pathway hyperactivation. Clinical trials are currently underway to establish the safety and efficacy of selective PI3Kδ inhibitors as a possible therapeutic option in patients with APDS. One is related to the oral administration of leniolisib (NCT02435173), the other to the inhaled administration of nemiralisib (NCT02993599). So far, the 12-week dose escalation of leniolisib has been shown to be safe and effective in reducing lymphadenopathy, splenomegaly, and cytopenia [144,147].

7. Conclusions

IEI is a group of rare diseases that can be camouflaged or not considered because of the predominant clinical features of atopy, autoimmunity, or lymphoproliferation. Consequently, some patients will remain undiagnosed. This risk impairs their quality of life, morbidity, and mortality, especially when exposed to agents reducing the immune competence. An underlying IEI should be particularly considered, especially in severe cases of atopic disease with concomitant signs of autoimmunity and unusual, recurrent or severe infections, so appropriate treatment regimens can be initiated and inappropriate immune suppression avoided.

In terms of the scientific evidence, it is still debatable whether allergy and cancer should be considered as risk factors or rather the consequences of the underlying IEI. Autoimmunity, as well as malignancy, worsen the IEI patients’ prognosis. Another important issue in IEI is their exact pathogenesis, as well as the gene–phenotype relationship. The recent advances in genetics also revolutionized the field of IEI. Until now, the increased use of new sequencing techniques allowed for the identification of different monogenic causes of IEI. They enabled the better understanding of genotype–phenotype correlations and consequently led to better therapeutic strategies targeting the immune dysregulation in IEI [45]. The unmet needs include the unified nomenclature; the pathophysiological
mechanisms assessment, for example, the lymphoma genesis in IEI patients; and better, more personalized treatment strategies [148].

Novel diagnostic approaches, as well as evidence-based treatment guidelines that consider the underlying immunodeficiency rather than using extrapolation from non-IEI settings, are necessary. The recommendations for validated screening of cohorts at risk of allergy, autoimmunity, and malignancy are of the utmost importance.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11144220/s1, Table S1: Diseases of immune dysregulation according to IUIS classification. Accessed on 8 July 2022.

Author Contributions: K.P.-Ś. and G.P. wrote the initial draft of this paper, which was critically revised by A.L.-U. and M.J. All the authors contributed to conceptualizing this work. All authors have read and agreed to the published version of the manuscript.

Funding: This research was financially supported by The Ministry of Health subvention according to number of STM.A020.20.063 from the IT Simple system of Wroclaw Medical University.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Tangye, S.G.; Al-Herz, W.; Bousfiha, A.; Cunningham-Rundles, C.; Franco, J.L.; Holland, S.M.; Klein, C.; Morio, T.; Oksenhendler, E.; Picard, C. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J. Clin. Immunol. 2022, 1–35. [CrossRef] [PubMed]
2. Bousfiha, A.; Jeddane, L.; Picard, C.; Al-Herz, W.; Ailal, F.; Chatila, T.; Cunningham-Rundles, C.; Etzioni, A.; Franco, J.L.; Holland, S.M.; et al. Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J. Clin. Immunol. 2020, 40, 66–81. [CrossRef] [PubMed]
3. Asano, T.; Boisson, B.; Onodi, F.; Matuozzo, D.; Moncada-Velez, M.; Maglorius Renkilaraj, M.; Zhang, P.; Meertens, L.; Bolze, A.; Materna, M.; et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 2021, 6, eabl4348. [CrossRef]
4. Solé, D. Primary immunodeficiencies: A diagnostic challenge? J. Pediatr. 2021, 97 (Suppl. S1), S1–S2. [CrossRef] [PubMed]
5. Ponsford, M.J.; Klocperk, A.; Pulvirenti, F.; Dalm, V.; Milota, T.; Cinetto, F.; Chovancova, Z.; Rial, M.J.; Sediva, A.; Litzman, J.; et al. Hyper-IgE in the allergy clinic—When is it primary immunodeficiency? Allergy 2018, 73, 2122–2136. [CrossRef] [PubMed]
6. Pieniawska-Śmiech, K.; Bar, K.; Babicki, M.; ´Smiech, K.; Lewandowicz-Uszynska, A.; Lewandowicz-Uszynska, A.; Pasternak, G.;´Swierkot, J.; Bogunia-Kubik, K. Primary Immunodeficiencies: Diseases of Children and Adults—A Review. Adv. Exp. Med. Biol. 2021, 1289, 37–54. [CrossRef]
7. Mauracher, A.A.; Gujer, E.; Bachmann, L.M.; Güsewell, S.; Schmid, J.P. Patterns of Immune Dysregulation in Primary Immunodeficiencies: A Systematic Review. J. Allergy Clin. Immunol. Pract. 2021, 9, 792–802.e10. [CrossRef]
8. Sokol, K.; Milner, J.D. The overlap between allergy and immunodeficiency. Curr. Opin. Pediatr. 2018, 30, 848–854. [CrossRef]
9. Lewandowicz-Uszynska, A.; Pasternak, G.; Świerkot, J.; Bogunia-Kubik, K. Primary Immunodeficiencies: Diseases of Children and Adults—A Review. Adv. Exp. Med. Biol. 2021, 1289, 37–54. [CrossRef]
10. Chan, S.K.; Gelfand, E.W. Primary Immunodeficiency Masquerading as Allergic Disease. Immunol. Allergy Clin. N. Am. 2015, 35, 767–778. [CrossRef]
11. Castagnoli, R.; Lougaris, V.; Giardino, G.; Volpi, S.; Leonardi, L.; La Torre, F.; Federici, S.; Corrente, S.; Cinicola, B.L.; Soresina, A.; et al. Inborn errors of immunity with atopic phenotypes: A practical guide for allergists. World Allergy Organ. J. 2021, 14, 100513. [CrossRef]
12. Lyons, J.J.; Milner, J.D. Primary atopic disorders. J. Exp. Med. 2018, 215, 1009–1022. [CrossRef]
13. Ozcan, E.; Notarangelo, L.D.; Geha, R.S. Primary immune deficiencies with aberrant IgE production. J. Allergy Clin. Immunol. 2008, 122, 1054–1064. [CrossRef]
14. Aghamohammadi, A.; Cheraghi, T.; Gharagozlou, M.; Movahedi, M.; Rezaei, N.; Yeganeh, M.; Parvaneh, N.; Abolhassani, H.; Pourpak, Z.; Moin, M. IgA deficiency: Correlation between clinical and immunological phenotypes. J. Clin. Immunol. 2009, 29, 130–136. [CrossRef]
15. Jacob, C.M.; Pastorino, A.C.; Fahl, K.; Carneiro-Sampaio, M.; Monteiro, R.C. Autoimmunity in IgA deficiency: Revisiting the role of IgA as a silent housekeeper. J. Clin. Immunol. 2008, 28 (Suppl. S1), S56–S61. [CrossRef]
16. Tuano, K.S.; Orange, J.S.; Sullivan, K.; Cunningham-Rundles, C.; Bonilla, F.A.; Davis, C.M. Food allergy in patients with primary immunodeficiency diseases: Prevalence within the US Immunodeficiency Network (USIDNET). J. Allergy Clin. Immunol. 2015, 135, 273–275. [CrossRef]

17. Lawrence, M.G.; Barber, J.S.; Sokolic, R.A.; Garabedian, E.K.; Desai, A.N.; O’Brien, M.; Jones, N.; Bali, P.; Hershfield, M.S.; Stone, K.D.; et al. Elevated IgE and atopy in patients treated for early-onset ADA-SCID. J. Allergy Clin. Immunol. 2013, 132, 1444–1446. [CrossRef]

18. Available online: https://primaryimmune.org/about-primary-immunodeficiencies-diagnosis-information/laboratory-tests (accessed on 17 February 2022).

19. Wittig, H.J.; Bellot, J.; De Fillippi, I.; Royal, G. Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J. Allergy Clin. Immunol. 1980, 66, 305–313. [CrossRef]

20. Anotegui, I.J.; Melioli, G.; Canonica, G.W.; Caraballo, L.; Villa, E.; Ebisawa, M.; Passalacqua, G.; Savi, E.; Ebo, D.; Gómez, R.M.; et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organ. J. 2020, 13, 100880. [CrossRef]

21. Lawrence, M.G.; Palacios-Kibler, T.V.; Workman, L.J.; Schuyler, A.J.; Steinke, J.W.; Payne, S.C.; McGowan, E.C.; Patrie, J.; Fuleihan, R.L.; Sullivan, K.E.; et al. Low Serum IgE Is a Sensitive and Specific Marker for Variable Immunodeficiency (CVID). J. Clin. Immunol. 2018, 38, 225–233. [CrossRef]

22. Mogensen, T.H. Primary Immunodeficiencies with Elevated IgE. Int. Rev. Immunol. 2016, 35, 39–56. [CrossRef] [PubMed]

23. Vu, Q.V.; Wada, T.; Toma, T.; Tajima, H.; Maeda, M.; Tanaka, R.; Oh-Ishi, T.; Yachie, A. Clinical and immunophenotypic features of atypical complete DiGeorge syndrome. Pediatr. Int. 2013, 55, 2–6. [CrossRef] [PubMed]

24. Adriani, M.; Aoki, J.; Horai, R.; Thornton, A.M.; Konno, A.; Kirby, M.; Anderson, S.M.; Siegel, R.M.; Candotti, F.; Schwartzberg, P.L. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin. Immunol. 2007, 124, 41–48. [CrossRef] [PubMed]

25. Humblet-Baron, S.; Sather, B.; Anover, S.; Becker-Herman, S.; Kasprowicz, D.J.; Khim, S.; Nguyen, T.; Hudkins-Loya, K.; Alpers, L.M.; et al. Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis. J. Immunol. 2013, 182, 381–389. [CrossRef] [PubMed]

26. Maillard, M.H.; Cotta-de-Almeida, V.; Takeshima, F.; Nguyen, D.D.; Michetti, P.; Nagler, C.; Bhan, A.K.; Snapper, S.B. The Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J. Invest. Immunol. 2007, 117, 407–418. [CrossRef]

27. Lexmond, W.S.; Goettel, J.A.; Lyons, J.J.; Jacobse, J.; Deken, M.M.; Lawrence, M.G.; DiMaggio, T.H.; Kotllarz, D.; Garabedian, E.; Sackstein, P.; et al. FOXP3+ Tregs require WASP to restrain Th2-mediated food allergy. J. Clin. Invest. 2016, 126, 4030–4044. [CrossRef] [PubMed]

28. Kumânovics, A.; Wittwer, C.T.; Pryor, R.J.; Augustine, N.H.; Leppert, M.F.; Carey, J.C.; Ochs, H.D.; Wedgwood, R.J.; Faville, R.J., Jr.; Quie, P.G.; et al. Rapid molecular analysis of the STAT3 gene in Job syndrome of hyper-IgE and recurrent infectious diseases. J. Mol. Diagn. 2010, 12, 213–219. [CrossRef]

29. Yong, P.F.; Freeman, A.F.; Engelhardt, K.R.; Holland, S.; Puck, J.M.; Grimbacher, B. An update on the hyper-IgE syndromes. Arthritis Res. Ther. 2012, 14, 228. [CrossRef]

30. Siegel, A.M.; Stone, K.D.; Cruse, G.; Lawrence, M.G.; Olivera, A.; Jung, M.Y.; Barber, J.S.; Freeman, A.F.; Holland, S.M.; O’Brien, M.; et al. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. J. Allergy Clin. Immunol. 2013, 132, 1388–1396. [CrossRef]

31. Hox, V.; O’Connell, M.P.; Lyons, J.J.; Sackstein, P.; Dimaggio, T.; Jones, N.; Nelson, C.; Boehm, M.; Holland, S.M.; Freeman, A.F.; et al. Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis. J. Allergy Clin. Immunol. 2016, 138, 187–199, Correction in J. Allergy Clin. Immunol. 2017, 140, 320. [CrossRef]

32. Boos, A.C.; Hagl, B.; Schlesinger, A.; Halm, B.E.; Ballenberger, N.; Pinarni, M.; Heinz, V.; Kreilinger, D.; Spielberger, B.D.; Schimke-Marques, L.F.; et al. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy 2014, 69, 943–953. [CrossRef]

33. Hill, H.R.; Quie, P.G.; Pabst, H.F.; Ochs, H.D.; Clark, R.A.; Klebanoff, S.J.; Wedgwood, R.J. Defect in neutrophil granulocyte chemotaxis in Job’s syndrome of recurrent “cold” staphylococcal abscesses. Lancet 1974, 304, 617–619. [CrossRef]

34. Grimbacher, B.; Holland, S.M.; Gallin, J.I.; Greenberg, E.; Hill, S.C.; Malech, H.L.; Miller, J.A.; O’Connell, A.C.; Puck, J.M. Hyper-IgE syndrome with recurrent infections—An autosomal dominant multisystem disorder. N. Engl. J. Med. 1999, 341, 692–702. [CrossRef]

35. Wellner, C.; Gertz, E.M.; Schäffer, A.A.; Lagos, M.; Perro, M.; Glocker, E.O.; Pietrogrande, M.C.; Cosso, F.; Franco, J.L.; Matamoros, N.; et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J. Allergy Clin. Immunol. 2010, 125, 424–432.e8. [CrossRef]

36. Hafsi, W.; Yarrarapu, S. Job syndrome. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2021.

37. Zhang, Q.; Davis, J.C.; Lamborn, I.T.; Freeman, A.F.; Jing, H.; Favreau, A.J.; Matthews, H.F.; Davis, J.; Turner, M.L.; Uzel, G.; et al. Combined immunodeficiency associated with DOCK8 mutations. N. Engl. J. Med. 2009, 361, 2046–2055. [CrossRef]

38. Wilkie, H.; Leyva-Castillo, J.M.; Janssen, E.; Geha, R.S. DOCK8 Deficiency Exacerbates Skin Contact Hypersensitivity: 194. J. Allergy Clin. Immunol. 2019, 143, AB64. [CrossRef]
39. Stites, D.P.; Ishizaka, K.; Fudenberg, H.H. Serum IgE concentrations in hypogammaglobulinaemia and selective IgA deficiency. Studies on patients and family members. Clin. Exp. Immunol. 1972, 10, 391–397.

40. Waldmann, T.A.; Polmar, S.H.; Balestra, S.T.; Jost, M.C.; Bruce, R.M.; Terry, W.D. Immunoglobulin E in immunologic deficiency diseases. II. Serum IgE concentration of patients with acquired hypogammaglobulinemia, thymoma and hypogammaglobulinemia, myotonic dystrophy, intestinal lymphangiectasia and Wiskott-Aldrich syndrome. J. Immunol. 1972, 109, 304–310.

41. Agondi, R.C.; Barros, M.T.; Rizzo, L.V.; Kalil, J.; Giavina-Bianchi, P. Allergic asthma in patients with common variable immunodeficiency. Allergy 2010, 65, 510–515. [CrossRef]

42. Agondi, R.C.; Barros, M.T.; Kokron, C.M.; Cohon, A.; Oliveira, A.K.; Kalil, J.; Giavina-Bianchi, P. Can patients with common variable immunodeficiency have allergic rhinitis? Am. J. Rhinol. Allergy 2013, 27, 79–83. [CrossRef]

43. Hartman, H.; Schneider, K.; Hintermeyer, M.; Bausch-Jurken, M.; Fuleihan, R.; Sullivan, K.E.; Cunningham-Rundles, C.; Bonilla, F.A.; USDINET Consortium; Verbsky, J. Lack of Clinical Hypersensitivity to Penicillin Antibiotics in Common Variable Immunodeficiency. J. Clin. Immunol. 2017, 37, 22–24. [CrossRef]

44. Schmidt, R.E.; Grimbacher, B.; Witte, T. Autoimmunity and primary immunodeficiency: Two sides of the same coin? Nat. Rev. Rheumatol. 2017, 14, 7–18. [CrossRef]

45. Costagliola, G.; Cappelli, S.; Consolini, R. Autoimmunity in Primary Immunodeficiency Disorders: An Updated Review on Pathogenic and Clinical Implications. J. Clin. Med. 2016, 5, 4729. [CrossRef]

46. Amaya-Uribe, L.; Rojas, M.; Azizi, G.; Anaya, J.M.; Gershwin, M.E. Primary immunodeficiency and autoimmunity: A comprehensive review. J. Autoimmun. 2019, 99, 52–72. [CrossRef]

47. Fischer, A.; Provot, J.; Jais, J.P.; Alcais, A.; Mahlaoui, N.; members of the CEREDIH French PID study group. Autoimmune and Inflammatory Manifestations Occur Frequently in Patients with Primary Immunodeficiencies. J. Allergy Clin. Immunol. 2017, 140, 1388–1393.e8. [CrossRef]

48. Azizi, G.; Ziaee, V.; Tavakol, M.; Alinea, T.; Yazdai, R.; Mohammadi, H.; Abolhassani, H.; Aghamohammadi, A. Approach to the Management of Autoimmunity in Primary Immunodeficiency. Scand. J. Immunol. 2017, 85, 13–29. [CrossRef]

49. Bertinchamp, R.; G.; Proietti, M.; Grimbacher, B.; Ehl, S.;Warnatz, K. Evaluating laboratory criteria for combined immunodeficiency in adult patients diagnosed with common variable immunodeficiency. Clin. Immunol. 2019, 203, 59–62. [CrossRef] [PubMed]

50. Speckmann, C.; Doerken, S.; Aiuti, A.; Albert, M.H.; Al-Herz, W.; Allende, L.M.; Scarselli, A.; Avcin, T.; Perez-Becker, R.; Cancrini, C. A prospective study on the natural history of patients with profound combined immunodeficiency: An interim analysis. J. Allergy Clin. Immunol. 2017, 139, 1302–1310.e4. [CrossRef] [PubMed]

51. Von Spee-Mayer, C.; Koemm, V.; Wehr, C.; Goldacker, S.; Kindle, G.; Bulashevska, A.; Proietti, M.; Grimbacher, B.; Ehl, S.;Warnatz, K. Evaluating laboratory criteria for combined immunodeficiency in adult patients diagnosed with common variable immunodeficiency. Clin. Immunol. 2019, 203, 59–62. [CrossRef] [PubMed]

52. Walter, J.E.; Ayala, I.A.; Milojevic, D. Autoimmunity as a continuum in primary immunodeficiency. Curr. Opin. Pediatr. 2019, 31, 851–862. [CrossRef] [PubMed]

53. Alroqi, F.J.; Charbonnier, L.M.; Baris, S.; Kiykim, A.; Chou, J.; Platt, C.D.; Algassim, A.; Keles, S.; Al Saud, B.K.; Alkuraya, F.S.; et al. Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation. J. Allergy Clin. Immunol. 2018, 141, 1050–1059.e10. [CrossRef]

54. Azizi, G.; Ahmadi, M.; Abolhassani, H.; Yazdani, R.; Mohammadi, H.; Mirshafiey, A.; Rezaei, N.; Aghamohammadi, A. Autoimmunity in Primary Antibody Deficiencies. Int. Arch. Allergy Immunol. 2016, 171, 180–193. [CrossRef]

55. Bruton, O.C. Agammaglobulinemia. Pediatrics 1952, 9, 722–728. [CrossRef]

56. Nonoyama, S.; Tsukada, S.; Yamadori, T.; Miyawaki, T.; Jin, Y.Z.; Watanabe, C.; Morio, T.; Yata, J.; Ochs, H.D. Functional analysis of peripheral B cells in patients with X-linked agammaglobulinemia. J. Immunol. 1998, 161, 3925–3929.

57. Jacobs, Z.D.; Fuleihan, R.; Sullivan, K.E.; Cunningham-Rundles, C.; Verbsky, J. Lack of Clinical Hypersensitivity to Penicillin Antibiotics in Common Variable Immunodeficiency. Scand. J. Immunol. 2017, 85, 13–29. [CrossRef]

58. Behniafard, N.; Aghamohammadi, A.; Abolhassani, H.; Pourjabbar, S.; Sabouni, F.; Rezaei, N. Autoimmunity in X-linked agammaglobulinemia: Kawasaki disease and review of the literature. Exp. Rev. Clin. Immunol. 2012, 8, 155–159. [CrossRef]

59. Fernandez-Trujillo, V.P.; Scalchunes, C.; Cunningham-Rundles, C.; Ochs, H.D.; Bonilla, F.A.; Paris, K.; Yel, L.; Sullivan, K.E. Autoimmunity and inflammation in X-linked agammaglobulinemia. J. Clin. Immunol. 2014, 34, 627–632. [CrossRef]

60. Ng, Y.S.; Wardemann, H.; Chelnis, J.; Cunningham-Rundles, C.; Meffre, E. Bruton’s tyrosine kinase is essential for human B cell tolerance. J. Exp. Med. 2004, 200, 927–934. [CrossRef]

61. Samuels, J.; Ng, Y.S.; Coupillaud, C.; Paget, D.; Meffre, E. Human B cell tolerance and its failure in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 2005, 1062, 116–126. [CrossRef]

62. Odnoletkova, I.; Kindle, G.; Quinti, I.; Grimbacher, B.; Knerr, V.; Gathmann, B.; Ehl, S.; Mahlaoui, N.; Van Wilder, P.; Bogerts, K. The burden of common variable immunodeficiency disorders: A retrospective analysis of the European Society for Immunodeficiency (ESID) registry data. Orphanet J. Rare Dis. 2018, 13, 201. [CrossRef]

63. Cunningham-Rundles, C. Autoimmunity in primary immune deficiency: Taking lessons from our patients. Clin. Exp. Immunol. 2011, 164 (Suppl. S2), 6–11. [CrossRef]

64. Grzesk, E.; Dabrowska, A.; Urbanczyk, A.; Ewertowska, M.; Wysocki, M.; Koltan, S. Common variable immunodeficiency: Different faces of the same disease. Postepy Dermatol. Alergol. 2021, 38, 873–880. [CrossRef]
65. Quinti, I.; Soresina, A.; Spadaro, G.; Martino, S.; Donnanno, S.; Agostini, C.; Claudio, P.; Franco, D.; Maria Pesce, A.; Borghese, F.; et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J. Clin. Immunol. 2007, 27, 308–316. [CrossRef]

66. Boileau, J.; Mouillot, G.; Gérard, L.; Carmagnat, M.; Rabian, C.; Oksenhendler, E.; Pasquali, J.L.; Korganow, A.S.; DEFI Study Group. Autoimmunity in common variable immunodeficiency: Correlation with lymphocyte phenotype in the French DEFI study. J. Autoimmun. 2011, 36, 25–32. [CrossRef]

67. Arandi, N.; Mirshafiey, A.; Jeddi-Tehrani, M.; Abolhassani, H.; Sadeghi, B.; Mirminachi, B.; Shaghaghi, M.; Aghamohammadi, A. Evaluation of CD4+/CD25+ FOXP3+ regulatory T cells function in patients with common variable immunodeficiency. Cell. Immunol. 2013, 281, 129–133. [CrossRef]

68. Carter, C.R.; Aravind, G.; Smalle, N.L.; Cole, J.Y.; Savic, S.; Wood, P.M. CVID patients with autoimmunity have elevated T cell expression of granzyme B and HLA-DR and reduced levels of Treg cells. J. Clin. Pathol. 2013, 66, 146–150. [CrossRef]

69. Yu, G.P.; Chiang, D.; Song, S.J.; Hoyte, E.G.; Huang, J.; Vanishsarn, C.; Nadeau, K.C. Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin. Immunol. 2009, 131, 240–253. [CrossRef]

70. Arumugakani, G.; Wood, P.M.; Carter, C.R. Frequency of Treg cells is reduced in CVID patients with autoimmunity and splenomegaly and is associated with expanded CD21lo B lymphocytes. J. Clin. Immunol. 2010, 30, 292–300. [CrossRef] [PubMed]

71. Chey, G.Y.; Sinha, U.; Gatenby, P.A.; DeMalmanche, T.; Adelstein, S.; Garcia, R.; Hissaria, P.; French, M.A.; Wilson, A.; Whittle, B. Autoimmunity in primary antibody deficiency is associated with protein tyrosine phosphatase nonreceptor type 22 (PTPN22). J. Allergy Clin. Immunol. 2013, 131, 1130.e1–1135.e1. [CrossRef] [PubMed]

72. Brouet, J.C.; Chedeville, A.; Fermand, J.P.; Royer, B. Study of the B cell memory compartment in common variable immunodeficiency. Eur. J. Immunol. 2000, 30, 2516–2520. [CrossRef]

73. Abolhassani, H.; Amirkashani, D.; Parvaneh, N.; Mohammadmnejad, P.; Gharib, B.; Shahinpoor, S. Autoimmune phenotype in patients with common variable immunodeficiency. J. Investig. Allergol. Clin. Immunol. 2013, 23, 323–329.

74. Picchianti Diamanti, A.; Rosado, M.M.; Scarsella, M.; Ceccarelli, S.; Laganò, B.; D’Amelio, R.; Carsetti, R. Increased serum IgM, immunodeficiency, and autoimmunity: A clinical series. Int. J. Immunopathol. Pharmacol. 2015, 28, 547–556. [CrossRef]

75. Lin, L.H.; Tsai, C.N.; Liu, M.F.; Wang, C.R. Common variable immunodeficiency mimicking rheumatoid arthritis with Sjögren’s syndrome. J. Microbiol. Infect. 2005, 38, 358–360.

76. Jesus, A.A.; Liphaus, B.L.; Silva, C.A.; Bando, S.Y.; Andrade, L.E.; Coutinho, A.; Carneiro-Sampaio, M. Complement and antibody primary immunodeficiency in juvenile systemic lupus erythematosus patients. Lupus 2011, 20, 1275–1284. [CrossRef]

77. European Association for the Study of the Liver. EASL clinical practice guidelines: Autoimmune hepatitis. J. Clin. Med. 2020, 9, 1181. [CrossRef]

78. European Association for the Study of the Liver. EASL clinical practice guidelines: Autoimmune hepatitis. J. Hepatol. 2015, 63, 971–1004. [CrossRef]

79. Pecoraro, A.; Crescenzini, L.; Varricchi, G.; Marone, G.; Spadaro, G. Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders. Front. Immunol. 2020, 11, 338. [CrossRef]

80. Tahiat, A.; Yagoubi, A.; Ladj, M.S.; Belbouab, R.; Aggoune, S.; Atek, L.; Bouziane, D.; Melzi, S.; Boubidi, C.; Drali, W.; et al. Diagnostic and Predictive Contribution of Autoantibodies Screening in a Large Series of Patients with Primary Immunodeficiencies. Front. Immunol. 2021, 12, 665322. [CrossRef]

81. Cheng, Y.K.; Decker, P.A.; O’Byrne, M.M.; Weiler, C.R. Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome. Ann. Allergy Asthma Immunol. 2006, 97, 306–311. [CrossRef]

82. Bennery, A.R.; Cant, A.J.; Jeggo, P.A. Immunodeficiency associated with DNA repair defects. Clin. Exp. Immunol. 2000, 121, 1–7. [CrossRef]

83. Vorechovsky, I.; Munzarova, M.; Lokaj, K. Increased IgM levels in lymphocytes of patients with common variable immunodeficiency indicates an involvement of chromosomal instability in their cancer predisposition. Cancer Immunol. Immunother. 1989, 29, 303–306. [CrossRef]

84. Gantt, R.; Parshad, R.; Price, F.M.; Sanford, K.K. Biochemical evidence for deficient DNA repair leading to enhanced G2 chromatid radiosensitivity and susceptibility to cancer. Radiat. Res. 1986, 108, 117–126. [CrossRef]

85. Rothblum-Oviatt, C.; Wright, J.; Lefton-Greif, M.A.; McGrath-Morrow, S.A.; Crawford, T.O.; Lederman, H.M. Ataxia telangiectasia: A review. Orphanet J. Rare Dis. 2016, 11, 159. [CrossRef]

86. Luzi, G.; Zullo, A.; Iebba, F.; Rinaldi, V.; Sanchez Mete, L.; Mucaritoli, M.; Aiuti, F. Duodenal pathology and clinical-immunological implications in common variable immunodeficiency patients. Am. J. Gastroenterol. 2003, 98, 118–121. [CrossRef]

87. Malamut, G.; Verkarre, V.; Suerrez, F.; Viaillard, J.F.; Lascaux, A.S.; Cosnes, J.; Bouhnik, Y.; Lambotte, O.; Béchade, D.; Zioli, M. The enteropathy associated with common variable immunodeficiency. Am. J. Gastroenterol. 2010, 105, 2262–2275. [CrossRef]

88. Daniels, J.A.; Lederman, H.M.; Maitra, A.; Montgomery, E.A. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): A clinicopathologic study and review. Am. J. Surg. Pathol. 2007, 31, 1800–1812. [CrossRef] [PubMed]

89. Westermann-Clark, E.; Meehan, C.A.; Meyer, A.K.; Dasso, J.F.; Amre, D.; Ellison, M.; Patel, B.; Betensky, M.; Hauk, C.I.; Mayer, J. Primary Immunodeficiency in Children with Autoimmune Cytopenias: Retrospective 154-Patient Cohort. Front. Immunol. 2021, 12, 649182. [CrossRef] [PubMed]
90. Mayor, P.C.; Eng, K.H.; Singel, K.L.; Abrams, S.I.; Odunsi, K.; Moysich, K.B.; Fuleihan, R.; Garabedian, E.; Lugar, P.; Ochs, H.D.; et al. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J. Allergy Clin. Immunol. 2018, 141, 1028–1035. [CrossRef] [PubMed]

91. Bonilla, F.A.; Barlan, I.; Chapel, H.; Costa-Carvalho, B.T.; Cunningham-Rundles, C.; de la Morena, M.T.; Espinosa-Rosales, F.J.; Hammarström, L.; Nonoyama, S.; Quinti, I. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J. Allergy Clin. Immunol. Pract. 2016, 4, 38–59. [CrossRef] [PubMed]

92. Gangemi, S.; Allegra, A.; Musolino, C. Lymphoproliferative disease and cancer among patients with common variable immunodeficiency. Leuk. Res. 2015, 39, 389–396. [CrossRef] [PubMed]

93. Cohen, J.M.; Sebire, N.J.; Harvey, J.; Gaspar, H.B.; Cathy, C.; Jones, A.; Rao, K.; Cubitt, D.; Amrolia, P.J.; Davies, E.G.; et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 2007, 110, 2209–2214. [CrossRef]

94. Teachey, D.T.; Seif, A.E.; Grupp, S.A. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Br. J. Haematol. 2010, 148, 205–216. [CrossRef]

95. Teachey, D.T.; Greiner, R.; Seif, A.; Attiyeh, E.; Blessing, J.; Choi, J.; Manno, C.; Rappaport, E.; Schwabe, D.; Sheen, C.; et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br. J. Haematol. 2009, 145, 101–106. [CrossRef]

96. Neven, B.; Magerus-Chatinet, A.; Florkin, B.; Gobert, D.; Lambotte, O.; De Somer, L.; Lanzarotti, N.; Stolzenberg, M.C.; Bader-Meunier, B.; Aladjidi, N. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 2011, 118, 4798–4807. [CrossRef]

97. Price, S.; Shaw, P.A.; Seitz, A.; Joshi, G.; Davis, J.; Niemela, J.E.; Perkins, K.; Hornung, R.L.; Folio, L.; Rosenberg, P.S. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 2014, 123, 1989–1999. [CrossRef]

98. Su, H.C.; Lenardo, M.J. Genetic defects of apoptosis and primary immunodeficiency. Immunol. Allergy Clin. N. Am. 2008, 28, 329–351. [CrossRef]

99. Oliveira, J.B. The expanding spectrum of the autoimmune lymphoproliferative syndromes. Curr. Opin. Pediatr. 2013, 25, 722–729. [CrossRef]

100. Pace, R.; Vinh, D.C. Autoimmune Lymphoproliferative Syndrome and Epstein-Barr Virus-Associated Lymphoma: An Adjunctive Diagnostic Role for Monitoring EBV Viremia? Case Rep. Immunol. 2013, 2013, 245893. [CrossRef]

101. Rao, V.K.; Carrasquillo, J.A.; Dale, J.K.; Bacharach, S.L.; Whatley, M.; Dugan, F.; Tretler, J.; Fleisher, T.; Puck, J.M.; Wilson, W. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). Am. J. Hematol. 2006, 81, 81–85. Correction in Am. J. Hematol. 2006, 81, 389. [CrossRef]

102. Bride, K.; Teachey, D. Autoimmune lymphoproliferative syndrome: More than a FASCinating disease. Curr. Opin. Hematol. 2012, 19, 305–312. [CrossRef]

103. Vajdic, C.M.; Mao, L.; van Leeuwen, M.T.; Kirkpatrick, P.; Grulich, A.E.; Riminton, S. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood 2010, 116, 1228–1234. [CrossRef]

104. Mellemkjaer, L.; Hammarström, L.; Andersen, V.; Yuen, J.; Heilmann, C.; Barington, T.; Bjorkander, J.; Olsen, J.H. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: A combined Danish and Swedish study. Clin. Exp. Immunol. 2002, 130, 495–500. [CrossRef]

105. Rezaei, N.; Hedayat, M.; Aghamohammadi, A.; Nichols, K.E. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J. Allergy Clin. Immunol. 2011, 127, 1329–1343. [CrossRef]

106. Taskinen, M.; Ranki, A.; Pukkala, E.; Jeskanen, L.; Kaitila, I.; Makité, O. Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. Am. J. Med. Genet. A 2008, 146, 2370–2375. [CrossRef]

107. Leechawengwongs, E.; Shearer, W.T. Lymphoma complicating primary immunodeficiency syndromes. Curr. Opin. Hematol. 2012, 19, 305–312. [CrossRef]

108. Ngalamika, O.; Zhang, Y.; Yin, H.; Zhao, M.; Gershwin, M.E.; Lu, Q. Epigenetics, autoimmunity and hematologic malignancies: A comprehensive review. J. Autoimmun. 2012, 39, 451–465. [CrossRef]

109. Dhalla, F.; da Silva, S.P.; Lucas, M.; Travis, S.; Chapel, H. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clin. Exp. Immunol. 2011, 165, 1–7. [CrossRef]

110. Quiding-Järbrink, M.; Sundström, P.; Lundgren, A.; Hansson, M.; Bäckström, M.; Johansson, C.; Enarsson, K.; Hermansson, M.; Johnsson, E.; Svennerholm, A.M. Decreased IgA antibody production in the stomach of gastric adenocarcinoma patients. Clin. Immunol. 2009, 131, 463–471. [CrossRef] [PubMed]

111. Cunningham-Rundles, C. The many faces of common variable immunodeficiency. Hematol. Am. Soc. Hematol. Educ. Program 2012, 2012, 301–305. [CrossRef]

112. Verma, N.; Thaventhiran, A.; Gathmann, B.; ESID Registry Working Party; Thaventhiran, J.; Grimbacher, B. Therapeutic management of primary immunodeficiency in older patients. Drugs Aging 2013, 30, 503–512. [CrossRef] [PubMed]

113. Ludvigsson, J.F.; Neovius, M.; Ye, W.; Hammarström, L. IgA deficiency and risk of cancer: A population-based matched cohort study. J. Clin. Immunol. 2015, 35, 182–188. [CrossRef]
De Miranda, N.F.; Björkman, A.; Pan-Hammarström, Q. DNA repair: The link between primary immunodeficiency and cancer. Am. N. Y. Acad. Sci. 2011, 1246, 50–63. [CrossRef]

Gennery, A.R. Primary immunodeficiency syndromes associated with defective DNA double-strand break repair. Br. Med. Bull. 2006, 77–78, 71–85. [CrossRef]

Carroll, C.; Badu-Nkansah, A.; Hunley, T.; Baradaran-Heravi, A.; Cortez, D.; Frangou, H. Schimke Imunoosseous Dysplasia associated with undifferentiated carcinoma and a novel SMARCAL1 mutation in a child. Pediatr. Blood Cancer 2013, 60, E88–E90. [CrossRef]

Baradaran-Heravi, A.; Raams, A.; Lubieniecka, J.; Cho, K.S.; DeHaai, K.A.; Basiratnia, M.; Mari, P.O.; Xue, Y.; Rauth, M.; Olney, A.H. SMARCAL1 deficiency predisposes to non-Hodgkin lymphoma and hypersensitivity to genotoxic agents in vivo. Am. J. Med. Genet. A 2012, 158, 2204–2213. [CrossRef]

Karalis, A.; Tischkowitz, M.; Millington, G.W. Dermatological manifestations of inherited cancer syndromes in children. Br. J. Dermatol. 2011, 164, 245–256. [CrossRef]

Hauck, F.; Voss, R.; Urban, C.; Seidel, M.G. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J. Allergy Clin. Immunol. 2018, 141, 59–68.e1. [CrossRef]

De Flora, S.; Bonanni, P. The prevention of infection-associated cancers. Carcinogenesis 2011, 32, 787–795. [CrossRef]

Meng, X.; Yang, B.; Suen, W.C. Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome. Innate Immun. 2018, 24, 4–10. [CrossRef]

Jacobsohn, D.A.; Emerick, K.M.; Scholl, P.; Melin-Aldana, H.; O’Gorman, M.; Duerst, R.; Kletzel, M. Nonmyeloablative hematopoietic stem cell transplant for X-linked hyper-immunoglobulin m syndrome with cholangiopathy. Pediatrics 2004, 113, e122–e127. [CrossRef]

Hayward, A.R.; Levy, J.; Facchetti, F.; Notarangelo, L.; Ochs, H.D.; Etzioni, A.; Bonnefoy, J.Y.; Cosyns, M.; Weinberg, A. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 1997, 158, 977–983.

Sokolic, R. Neutropenia in primary immunodeficiency. Curr. Opin. Hematol. 2013, 20, 35–65. [CrossRef]

Meng, X.; Yang, B.; Suen, W.C. Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome. Innate Immun. 2018, 24, 4–10. [CrossRef]

Jacobsohn, D.A.; Emerick, K.M.; Scholl, P.; Melin-Aldana, H.; O’Gorman, M.; Duerst, R.; Kletzel, M. Nonmyeloablative hematopoietic stem cell transplant for X-linked hyper-immunoglobulin m syndrome with cholangiopathy. Pediatrics 2004, 113, e122–e127. [CrossRef]

Hayward, A.R.; Levy, J.; Facchetti, F.; Notarangelo, L.; Ochs, H.D.; Etzioni, A.; Bonnefoy, J.Y.; Cosyns, M.; Weinberg, A. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 1997, 158, 977–983.

Hauck, F.; Voss, R.; Urban, C.; Seidel, M.G. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J. Allergy Clin. Immunol. 2018, 141, 59–68.e1. [CrossRef]

De Flora, S.; Bonanni, P. The prevention of infection-associated cancers. Carcinogenesis 2011, 32, 787–795. [CrossRef]

Meng, X.; Yang, B.; Suen, W.C. Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome. Innate Immun. 2018, 24, 4–10. [CrossRef]

Jacobsohn, D.A.; Emerick, K.M.; Scholl, P.; Melin-Aldana, H.; O’Gorman, M.; Duerst, R.; Kletzel, M. Nonmyeloablative hematopoietic stem cell transplant for X-linked hyper-immunoglobulin m syndrome with cholangiopathy. Pediatrics 2004, 113, e122–e127. [CrossRef]

Hayward, A.R.; Levy, J.; Facchetti, F.; Notarangelo, L.; Ochs, H.D.; Etzioni, A.; Bonnefoy, J.Y.; Cosyns, M.; Weinberg, A. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 1997, 158, 977–983.

Grierson, H.L.; Skare, J.; Hawk, J.; Pauza, M.; Pertiko, D.T. Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease. Am. J. Med. Genet. 1991, 40, 294–297. [CrossRef]

Rezaei, N.; Mahmoudi, E.; Aghamohammadi, A.; Das, R.; Nichols, K.E. X-linked lymphoproliferative syndrome: A genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br. J. Haematol. 2011, 152, 13–30. [CrossRef]

Conrado, L.A.; Marques, S.A.; Lastoria, J.C.; Cucé, L.C.; Marques, M.E.; Dillon, N.L. Keratitis-ichthyosis-deafness (KID) syndrome with squamous cell carcinoma. Int. J. Dermatol. 2007, 46, 403–406. [CrossRef]

Natsuga, K.; Akiyama, M.; Shimizu, H. Malignant skin tumours in patients with inherited ichthyosis. Br. J. Dermatol. 2011, 165, 263–268. [CrossRef]

Filippovich, A.H.; Mathur, A.; Kamat, D.; Shapiro, R.S. Primary immunodeficiencies: Genetic risk factors for lymphoma. Cancer Res. 1992, 52 (Suppl. S19), 5465s–5467s.

Broeks, A.; Urbanus, J.H.; Floore, A.N.; Dahler, E.C.; Klijn, J.G.; Rutgers, E.J.; Devilee, P.; Russell, N.S.; Van Leeuwen, F.E.; Van’t Veer, L.J. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am. J. Hum. Genet. 2000, 66, 494–500. [CrossRef]

Jerzak, K.J.; Mancuso, T.; Eisen, A. Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: A narrative review. Curr. Oncol. 2018, 25, e176–e180. [CrossRef]

Kiymik, A.; Eker, N.; Surekli, O.; Nain, E.; Kasap, N.; Aktürk, H.; Dogru, O.; Canbolat, A.; Somer, A.; Koc, A. Malignancy and lymphoid proliferation in primary immune deficiencies; hard to define, hard to treat. Pediatr. Blood Cancer 2020, 67, e28091. [CrossRef]

Seidemann, K.; Tiemann, M.; Henze, G.; Sauerbrey, A.; Müller, S.; Reiter, A. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: Analysis of 19 patients from the BFM trials. Med. Pediatr. Oncol. 1999, 33, 536–544. [CrossRef]

Bomken, S.; Van der Werff Ten Bosch, J.; Attarbaschi, A.; Bacon, C.M.; Borkhardt, A.; Boztug, K.; Fischer, U.; Hauck, F.; Kuiper, R.P.; Lammens, T.; et al. Current Understanding and Future Research Priorities in Malignancy Associated with Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group. Front. Immunol. 2018, 9, 2912. [CrossRef]
139. Gompels, M.M.; Hodges, E.; Lock, R.J.; Angus, B.; White, H.; Larkin, A.; Chapel, H.M.; Spickett, G.P.; Misbah, S.A.; Smith, J.L.; et al. Lymphoproliferative disease in antibody deficiency: A multi-centre study. *Clin. Exp. Immunol.* **2003**, *134*, 314–320. [CrossRef]

140. Ren, A.; Yin, W.; Miller, H.; Westerberg, L.S.; Candotti, F.; Park, C.S.; Lee, P.; Gong, Q.; Chen, Y.; Liu, C. Novel Discoveries in Immune Dysregulation in Inborn Errors of Immunity. *Front. Immunol.* **2021**, *12*, 725887. [CrossRef]

141. Fournier, B.; Tusseau, M.; Villard, M.; Malcus, C.; Chopin, E.; Martin, E.; Jorge Cordeiro, D.; Fabien, N.; Fusaro, M.; Gauthier, A. DEF6 Deficiency, A Mendelian Susceptibility to EBV Infection, Lymphoma, and Autoimmunity. *J. Allergy Clin. Immunol.* **2021**, *147*, 740–743.e9. [CrossRef]

142. Somekh, I.; Thian, M.; Medgyesi, D.; Gülez, N.; Magg, T.; Gallón Duque, A.; Stauber, T.; Lev, A.; Genel, F.; Unal, E.; et al. CD137 Deficiency Causes Immune Dysregulation with Predisposition to Lymphomagenesis. *Blood* **2019**, *134*, 1510–1516. [CrossRef]

143. Salzer, E.; Zoghi, S.; Kiss, M.G.; Kage, F.; Rashkova, C.; Stahnke, S.; Haimel, M.; Platzer, R.; Caldera, M.; Ardy, R.C.; et al. The Cytoskeletal Regulator HEM1 Governs B Cell Development and Prevents Autoimmunity. *Sci. Immunol.* **2020**, *5*, eabc3979. [CrossRef]

144. Delmonte, O.M.; Castagnoli, R.; Calzoni, E.; Notarangelo, L.D. Inborn Errors of Immunity with Immune Dysregulation: From Bench to Bedside. *Front. Pediatr.* **2019**, *7*, 353. [CrossRef] [PubMed]

145. Perez, E. Future of Therapy for Inborn Errors of Immunity. *Clin. Rev. Allergy Immunol.* **2022**, 1–15. [CrossRef] [PubMed]

146. Hoyos-Bachiloglu, R.; Platt, C. Precision Medicine as Treatment for Primary Immunodeficiency and Immune Dysregulation. *Immunol. Genet. J.* **2019**, *2*, 153–172.

147. Rao, V.K.; Webster, S.; Dalm, V.; Šedivá, A.; Van Hagen, P.M.; Holland, S.; Rosenzweig, S.D.; Christ, A.D.; Sloth, B.; Cabanski, M. Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. *Blood* **2017**, *130*, 2307–2316. [CrossRef]

148. Riaz, I.B.; Faridi, W.; Patnaik, M.M.; Abraham, R.S. A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients with Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity). *Front. Immunol.* **2019**, *10*, 777. [CrossRef]